Global HCQ/CQ studies

September 3, 2023

@CovidAnalysis

551 HCQ COVID-19 studies, 425 peer reviewed, 408 comparing treatment and control groups. Late treatment and high dosages may be harmful, while early treatment consistently shows positive results. Negative evaluations typically ignore treatment delay. Some *In Vitro* evidence suggested therapeutic levels would not be reached, however that was incorrect [Ruiz]. Recent: Shu-Han Lin Wen Afsin de Reus White Connor Okasha. HCQ/CQ was adopted in all or part of 42 countries (57 including non-government medical organizations). Submit updates/corrections.

	S	earch		HCQ	All
44929	Covid Analys		HCQ for COVID-19: real-time m	•	
Aug 28			Repurposed drug studies on th mitations/biases, including many r		
Aug 75			Inhalable Chitosan-Based Hydral administration of HCQ + chitosal	_	
Aug 17			The In Vitro, In Vivo, and PBPK lation of HCQ showing sustained o		
Aug 5	,		Impact of prophylactic hydroxy preferential protection for early tar	•	'
Aug 7	-		Factors affecting prognosis and ospective 80 hospitalized severe C		•
Jul 37		., CMAJ Open, d ement (p=0.15). Long	Patient-reported outcomes of raterm neurologic and neuropsychi	•	
JU/25			Cholinergic α7 nAChR signaling g that activating α7 nAChR with th		

JW 1>	Shamsi et al., Canadian Journ Survival and Mortality in Hospitalized Children with COVID-19: A Referral 39% higher mortality (p=0.51). Retrospective 183 hospitalized pediatric COVID-19 patients in Iran, showing no
JM 12	Kamga Kapchoup et al., Front In vitro effect of hydroxychloroquine on pluripotent stem cells and their c In vitro study of HCQ with mouse and human pluripotent stem cells and their cardiomyocyte derivatives. Result
1/11/	Klebanov et al., Journal of Dr Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19 31% lower mortality (p =0.8) and 6% more cases (p =0.7). Retrospective 3,074 patients with antimalarial prescri
Jun 29	Finkelstein et al., Studies in H The Efficacy of Long-Term Hydroxychloroquine Use in the Prevention of C 21% fewer cases (p=0.0007). PSM retrospective SLE/RA patients in the USA, showing lower COVID-19 cases wi
OE UN	Milan Bonotto et al., Antiviral Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 inf In Vitro study showing that CatB inhibitors including nitroxoline and its derivatives significantly impair SARS-Co
55 mg	Brouqui et al., New Microbes There is no such thing as a Ministry of Truth and why it is important to ch Discussion of censorship in scientific journals and the media; fraudulent, false, and misleading information use
Jun 20	Cárdenas-Jaén et al., Gastroe Gastrointestinal symptoms and complications in patients hospitalized du 56% lower severe cases (p=0.13). Retrospective 829 hospitalized COVID-19 patients in Spain focused on gastr
Jun 1>	de Gonzalo-Calvo et al., Respi A blood microRNA classifier for the prediction of ICU mortality in COVID 38% lower mortality (p=0.23). Retrospective 491 ICU patients in Spain showing lower mortality with HCQ witho
Jun 16	Hong et al., BMJ Open, doi:1 Safety and efficacy of hydroxychloroquine as prophylactic against COVID Meta analysis of 10 RCTs showing lower COVID-19 cases with HCQ, without statistical significance. This analy
Jun 10	Wade et al., Value in Health, d Variation in Demographic Characteristics, Socioeconomic Status, Clinica Retrospective analysis of mortality for COVID-19 patients in the USA. Authors do not provide adjusted results,
Jun 1	Rathod et al., The Journal of t Risk Factors associated with COVID-19 Patients in India: A Single Center 73% lower mortality (p=0.02). Retrospective 565 COVID-19 patients 5 days from symptom onset in India, show
Jun 1	Rudraraju et al., Stem Cell Re Parallel use of human stem cell lung and heart models provide insights f In Vitro study showing that SARS-CoV-2 cell entry differs across cell types. ACE2 was required for infection in b
May 30 May 37	Dulcey et al., Journal of Clinic Long-Term Hydroxychloroquine and Its Association with Covid-19 Infecti 21% fewer cases (p=0.27). PSM retrospective 322 rheumatological patients on HCQ and 645 matched control
May	Gutte et al., Indian Journal of QTc Interval of Healthcare Workers from India: Baseline and Effect of Hyd

Prospective study of 250 healthcare workers in India, showing no signficant change in QTc interval with HCQ p...



Souza Neves, F., Infectious Di... Does Widespread Use of Hydroxychloroquine Reduce the Transmissibilit... Analysis of 7 states in Brazil showing that consumption of HCQ was a significant negative predictor of the COV...



Yilgwan et al., Nigerian Medic... Clinical profile and Predictors of Outcomes of Hospitalized Patients with ... 93% lower mortality (p<0.0001). Retrospective 3,462 hospitalized COVID-19 patients across 13 states in Nigier...



AlQadheeb et al., Clinical Infe... Impact of common comorbidities on antimicrobial consumption and mo... 35% lower mortality (p=0.0001). Retrospective 848 ICU patients in Saudi Arabia, showing lower mortality with ...



Galgate et al., Journal of Coa... Formulation and Evaluation of Hydroxychloroquine Sulfate Nasal Spray f... Formulation and testing of a HCQ nasal spray for improved bioavailability and prolonged release.



Said et al., Journal of Multidis... Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients... 78% lower mortality (p<0.0001). Retrospective 750 COVID-19 patients in Saudi Arabia, showing lower mortality...



Loo et al., Pharmaceutical Re... Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeu...
Review of nanoformulations for inhaled therapeutics for respiratory viral infections including COVID-19. Inhaled...



Sen et al., The Lancet Rheum... Post-COVID-19 condition in patients with autoimmune rheumatic diseas... 40% lower PASC (p=0.08). Retrospective 755 autoimmune rheumatic disease patients, showing lower risk of P...



Krishnan et al., The American ... Predictors of Mortality among Patients Hospitalized with COVID-19 durin... 40% lower mortality (p=0.05). Case control study with 2,431 hospitalized COVID-19 patients in India, showing I...



Million et al., medRxiv, doi:10.... Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life ... 59% lower mortality (p=0.008). Retrospective 30,423 patients in France, showing very low mortality overall for ...



Ho et al., Malaysian Journal o... Hydroxychloroquine for COVID-19: A Single Center, Retrospective Cohort... 890% higher progression (p=0.03). Retrospective 325 hospitalized COVID-19 patients in Malaysia, showing hig...



Aweimer et al., Scientific Rep... Mortality rates of severe COVID-19-related respiratory failure with and wi... 40% lower mortality (p=0.12). Retrospective 149 patients under invasive mechanical ventilation in Germany sh...



Chevalier et al., Frontiers in M... CovAID: Identification of factors associated with severe COVID-19 in pati... 35% lower mortality (p=0.19) and 19% lower hospitalization (p=0.36). Retrospective 1,213 rheumatic disease p...



Brouqui et al., Authorea, Inc., ... Viral clearance in patients with COVID-19: associated factors and the rol... 15% improved viral clearance (p=0.04). Retrospective 1,276 patients in France, showing faster viral clearance ...

War 1>	Million et al., MDPI AG, doi:10 Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID Retrospective 424 consecutive patients in France showing that HCQ+AZ treatment was safe for early stage CO
Mar 2	Spivak et al., Microbiology Sp A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of 73% higher hospitalization (p =0.54), 20% improved recovery (p =0.19), and 17% improved viral clearance (p =0
Feb 28	Mathew et al., Rheumatology Predictors of COVID-19 severity and outcomes in Indian patients with rhe 20% lower mortality (p =0.8), no change in hospitalization (p =0.94), and 40% lower severe cases (p =0.37). Pros
F6628	Llanos-Cuentas et al., BMC R Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare 69% more cases (p=0.46). Early terminated healthcare worker PrEP RCT with only 68 patients and 8 cases, sho
Feb 20	Delgado et al., Research Squa Investigational medications in 9,638 hospitalized patients with severe C 26% lower mortality (p=0.002). PSM retrospective 9,638 patients in the USA, showing significantly lower morta
Feb 15	Alshamrani et al., Saudi Phar Comprehensive evaluation of six interventions for hospitalized patients w 50% lower mortality (p =0.18), 37% lower progression (p =0.21), 9% shorter ICU admission (p =0.66), and 3% lo
Jan 2>	Nasri et al., Advanced Biome Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory 92% fewer symptomatic cases (p=0.03). RCT 143 healthcare workers in Iran, showing lower cases with HCQ p
Jan 19	Alam et al., MDPI AG, doi:10 Towards Predicting Length of Stay and Identification of Cohort Risk Fact Deep learning model for the prediction of hospitalization time for COVID-19 based on 311 patients in Saudi Ara
Jan 16	Viglione et al., The Gazette of Intravenous high dose vitamin C and ozonated saline effective treatment Retrospective 479 high risk outpatients in the USA treated with a protocol including intravenous vitamin C, vita
Jan 16	Asadi et al., Journal of Pharm Effectiveness of different treatment regimens on patients with COVID-19, Retrospective 660 hospitalized patients in Iran comparing 6 different drug regimens: 1. HCQ or CQ+AZ, 2. inter
Jan 13	Hawari et al., Journal of Aero Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroqui Analysis of a nebulized HCQ formulation with 12 healthy patients, showing low systemic concentrations and s
Janz	Dhibar et al., Scientific Report The 'myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (P 27% fewer symptomatic cases (p=0.32) and 21% fewer cases (p=0.21). Low dose low-risk patient HCQ PEP RC
Dec 37 Jan 4 2022	Mitjà et al., Clinical and Transl Hydroxychloroquine for treatment of non-hospitalized adults with COVID 33% improved viral clearance (p=0.02). Extremely high COI (includes authors of trials playing a key role in the s
0ec 202	Genton et al., NCT04385264 #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisa

Estimated 800 patient HCQ early treatment RCT with results not reported over 8 months after estimated comp...



Higgins et al., JAMA, doi:10.1... Long-term (180-Day) Outcomes in Critically III Patients With COVID-19 in ... 51% higher mortality (p=0.06). Long-term followup for the REMAP-CAP very late stage ICU trial, showing higher...



Shukla et al., The Lancet Regi... An observational multi-centric COVID-19 sequelae study among health c... 5% lower PASC (p=0.78). Retrospective 679 healthcare workers post COVID-19 discharge, 76 using HCQ prop...



Shahrin et al., Life, doi:10.339... Hospital-Based Quasi-Experimental Study on Hydroxychloroquine Pre-Ex... 88% more cases (p=0.09). Retrospective 230 low risk healthcare workers taking HCQ prophylaxis, and 106 tha...



Alosaimi et al., Pharmaceutic... Analyzing the Difference in the Length of Stay (LOS) in Moderate to Sever... 400% higher mortality (p=0.49), 43% shorter hospitalization (p=0.63), and 29% higher hospital discharge (p=0....



Landsteiner de Sampaio Amê... COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs:... 24% lower mortality (p=0.01) and 20% lower hospitalization (p=0.04). Systematic review and meta analysis of ...



Bubenek-Turconi et al., Europ... Clinical characteristics and factors associated with ICU mortality during t... 22% lower mortality (p=0.01). Prospective study of 9,058 COVID-19 ICU patients in Romania, showing lower m...



Sukumar et al., F1000Resear... The Frontline War: A Case-control study of risk factors for COVID-19 am... 38% fewer cases (p=0.3). Case control study of healthcare workers in India, showing lower risk of cases with H...



Patel et al., Seminars in Arthri... Factors Associated with COVID-19 Breakthrough Infection Among Vacci... 41% fewer cases (p=0.02). Retrospective 11,468 vaccinated rheumatic disease patients, showing lower risk of ...



Assad, H., Current Issues in P... Pharmacotherapy prescribing pattern and outcome for hospitalized patie... 60% lower mortality (p=0.002). Retrospective 346 hospitalized patients in Iraq, showing lower mortality with H...



Cosentino et al., Journal of Cl... Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392... Retrospective 392 outpatients in Italy showing 0.2% mortality with early treatment, compared with >3% in Italy...



Gómez et al., Medicina Clínic... Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibr... 36% lower mortality (p<0.0001). Retrospective 1,799 hospitalized COVID-19 patients with atrial fibrillation in S...



Isnardi et al., Clinical Rheuma... Sociodemographic and clinical factors associated with poor COVID-19 o... 34% lower mortality (p=0.23), 48% lower severe cases (p=0.02), and 17% lower hospitalization (p=0.09). Retro...



Obrișcă et al., Biomedicines, ... Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort ... 87% fewer cases (p=0.01). Prospective analysis of 95 Lupus Nephritis patients in Romania, showing lower risk ...



Go et al., Frontiers in Pharma... Hydroxychloroguine, azithromycin and methylprednisolone and in hospit... 55% lower mortality (p=0.03). Retrospective 759 hospitalized patients in the USA, showing lower mortality with...



Guillaume et al., Rheumatolo... Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infectio... 2% higher hospitalization (p=1) and 3% more cases (p=0.96). Retrospective 459 SLE, RA, SjS, or PsA patients i...



Yuan et al., Communications ... Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathwa... In Vitro study showing that HCQ blocks SARS-CoV-2 entry into the endocytic pathway, and that HCQ was more...



Development of SARS-CoV-2 infection in patients with rheumatic conditi... **Gentry** et al., The American J... 12% lower mortality (p=0.99), 12% lower hospitalization (p=0.81), and 14% more cases (p=0.57). Updated vers...



Núñez-Gil et al., Anti-Infective... Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- C... 53% lower mortality (p<0.0001). PSM retrospective 6,217 hospitalized patients in Spain, showing lower mortali...



Sahebari et al., Reumatologia... Influence of biologic and conventional disease-modifying antirheumatic ... 56% fewer cases (p=0.02). Retrospective 512 rheumatic disease patients in Iran, showing lower risk of COVID-...



Oku et al., Modern Rheumatol... Risk factors for hospitalization or mortality for COVID-19 in patients with ... 92% lower mortality (p=1) and 12% lower hospitalization (p=0.34). Retrospecttive 220 COVID-19 patients with ...



Flores-Chavez et al., Clinical ... SARS-CoV-2 infection in 898 patients with Sjögren's syndrome: characte... Retrospective 898 patients with Sjögren's disease, showing a lower risk of worse outcomes with HCQ compar...



Babayigit et al., Frontiers in M... The association of antiviral drugs with COVID-19 morbidity: The retrospe... 112% higher ventilation (p=0.21), 53% higher ICU admission (p=0.33), and 17% longer hospitalization (p=0.05)...



Bowen et al., Open Forum Inf... Reduction in risk of death among patients admitted with COVID-19 betw... 20% lower mortality (p=0.007). Retrospective 4,631 hospitalized patients in New York, showing higher mortalit...



Loucera et al., medRxiv, doi:1... Real-world evidence with a retrospective cohort of 15,968 Andalusian C... 69% lower mortality (p=0.0002). Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower ...



Lyashchenko et al., British Jo... Systemic Exposure to Hydroxychloroquine and its relationship with outc... 48% higher mortality (p<0.0001). Retrospective very late stage hospitalized patients in New York during the firs...



García-Albéniz et al., Europea... Systematic review and meta-analysis of randomized trials of hydroxychlo... 28% fewer cases (p=0.003). Systematic review and meta-analysis of HCQ prophylaxis RCTs showing a statistic...

de Reus et al., PLOS ONE, doi... Tolerability and pharmacokinetic evaluation of inhaled dry powder hydro...

Tolerability and pharmacokinetic evaluation of an inhaled dry powder formulation of HCQ. Inhaled HCQ was ge...



Becetti et al., Qatar Medical J... Prevalence of coronavirus disease 2019 in a multiethnic cohort of patien... 37% fewer cases (p=0.17). Retrospective 700 patients with autoimmune rheumatic disease in Qatar, showing l...



Polo et al., Clinical Microbiolo... Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine... 51% fewer symptomatic cases (p=0.79) and 27% fewer cases (p=0.31). Early terminated healthcare worker pro...



Xu et al., Rapid Communicati... A study of impurities in the repurposed COVID-19 drug hydroxychloroqui...

Analysis of HCQ from two manufacturers showing 9 different impurities, with significantly different concentrati...



Hawari et al., NCT05113810 The Potential Use of Nebulized Hydroxychloroquine for the Treatment of ... Estimated 110 patient HCQ nebulized late treatment RCT with results not reported over 1 year after estimated ...



Patel et al., medRxiv, doi:10.1... Factors Associated with COVID-19 Breakthrough Infection in the Pre-Om... 46% fewer cases (p=0.001). Retrospective 11,468 vaccinated rheumatic disease patients in the USA, showing I...



Malundo et al., IJID Regions, ... Predictors of Mortality among inpatients with COVID-19 Infection in a Ter... 24% higher mortality (p=0.32). Retrospective 1,215 hospitalized patients in the Phillipines, showing no significa...



Yadav et al., Indian Journal of ... Hydroxychloroquine/chloroquine prophylaxis among health-care workers... 20% lower seropositivity (p=0.1). Retrospective 2,224 healthcare workers in India, showing lower risk of serop...



Raabe et al., medRxiv, doi:10.... Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 a... 82% fewer symptomatic cases (p=0.17). Small prophylaxis study with 130 healthcare workers in the USA, sho...



Osawa et al., The Journal of C... Characteristics and risk factors for mortality in critically ill patients with C... 29% lower mortality (p=0.07). Retrospective 215 mechanically ventilated COVID-19 patients in Brazil, 71 treate...



Ghanem-Zoubi et al., NCT044... Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (... Estimated 582 participant HCQ prophylaxis RCT with results not reported over 1 year after estimated completi...



Nimitvilai et al., Journal of Glo... A randomized controlled trial of combined ivermectin and zinc sulfate ve... 50% worse viral clearance (p=0.12). RCT low-risk patients in Thailand comparing HCQ, darunavir/ritonavir, and ...



Tirupakuzhi Vijayaraghavan e... Hydroxychloroquine plus personal protective equipment versus personal ... 196% higher progression (p=1), 52% lower hospitalization (p=0.62), and 14% fewer cases (p=0.73). Low-dose ...



Silva et al., Frontiers in Cellula... Clinical-Epidemiology Aspect of Inpatients With Moderate or Severe COV... 46% higher mortality (p=0.22). Retrospective 395 hospitalized patients in Brazil, showing higher mortality with ...



Gkioulekas et al., Authorea, In... Frequentist and Bayesian analysis methods for case series data and appl... Hybrid statistical framework for evaluating treatment protocols. COVID-19 treatment protocols often use risk s...



Hong et al., PLOS ONE, doi:1... Use of combined treatment of 3rd-generation cephalosporin, azithromyc... 25% faster recovery (p=0.45), 13% longer hospitalization (p=0.75), and no change in viral clearance (p=0.99). R...



Bassets-Bosch et al., Anales ... Negativización de PCR a SARS-CoV-2 en muestra respiratoria en pacient... 29% faster viral clearance (p=0.45). Retrospective 15 pediatric patients in Spain, showing faster viral clearance...



Satti et al., Cureus, doi:10.77... Characteristics and Obstetric Outcomes in Women With Autoimmune Rh... 61% fewer cases (p=0.04). Retrospective 80 consecutive pregnant patients with autoimmune rheumatic diseas...



Faísca et al., Pharmaceutics, ... Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids a... In Vitro study showing improved antiviral activity with ionic formulations of HCQ.



Roy-García et al., medRxiv, do... Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azi... Small early terminated RCT in Mexico with 31 HCQ and 31 control patients, showing higher progression with tr...



Hafez et al., Antibiotics, doi:1... Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till... 12% faster viral clearance (p=0.59). Retrospective hospitalized patients in the United Arab Emirates, showing n...



Walbi et al., Journal of Interna... Effect of chronic hydroxychloroquine use on COVID-19 risk in patients wi... Retrospective RA/SLE patients in Saudi Arabia. Numbers in this paper are contradictory. Figure 1 and the introd...



Delandre et al., Pharmaceutic... Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical ... In Vitro study with 30 COVID-19 strains from 14 variants, showing stronger efficacy with ivermectin compared ...



Avezum et al., The Lancet Re... Hydroxychloroquine versus placebo in the treatment of non-hospitalised ... 1% lower mortality (p=1), 32% higher ventilation (p=0.79), 16% lower ICU admission (p=0.61), and 23% lower ...



Gagneux-Brunon et al., Trials,... Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxyc... 118 participant HCQ prophylaxis RCT with results not reported over 1 year after completion.



MacFadden et al., Open Foru... Screening Large Population Health Databases for Potential COVID-19 Th... 12% fewer cases (p=0.01). Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing low...



AlQahtani et al., Scientific Re... Randomized controlled trial of favipiravir, hydroxychloroquine, and stand... 4% improved recovery (p=0.94) and 47% improved viral clearance (p=0.13). RCT with 54 favipiravir, 51 HCQ, an...

White et al., COPCOV, NCT04... Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (CO...

4,652 participant HCQ prophylaxis RCT with results not reported over 1 year after completion.



Oztas et al., Journal of Medic... Frequency and Severity of COVID-19 in Patients with Various Rheumatic ... 215% higher hospitalization (p=0.36), 40% more symptomatic cases (p=0.44), and 5% more cases (p=0.88). R...



Ragonnet et al., Future Pharm... Drug Repositioning in Intensive Care Patients and Pharmacokinetic Varia... Comparison of two HCQ dosing regimens, showing high inter-individual variability of HCQ concentrations (as i...



Ebongue et al., Travel Medicin... Factors predicting in-hospital all-cause mortality in COVID 19 patients at ... 43% lower mortality (p=0.04). Retrospective 580 hospitalized COVID+ patients in Cameroon, showing lower m...



Uyaroğlu et al., Acta Medica, ... Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in th... 200% higher mortality (p=1), 67% lower ICU admission (p=1), and 10% shorter hospitalization (p=0.9). PSM re...



Salehi et al., Research Square... Risk factors of death in mechanically ventilated COVID-19 patients: a retr... 14% higher mortality (p=0.44). Retrospective 125 mechanically ventilated ICU patients in Iran, showing no signi...



Azaña Gómez et al., Medicina... Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibr... 36% lower mortality (p<0.0001). Retrospective 1,816 COVID-19 patients with atrial fibrillation in Spain, showin...



Tsanovska et al., Infectious Di... Hydroxychloroquine (HCQ) treatment for hospitalized patients with COVI... 58% lower mortality (p=0.03), 74% lower ventilation (p=0.0007), and 70% lower ICU admission (p=0.0004). PS...



Soto et al., PLOS ONE, doi:10.... Mortality and associated risk factors in patients hospitalized due to COVI... 6% higher mortality (p=0.46). Retrospective 1,418 very late stage (46% mortality) patients in Peru, showing no ...



Rouamba et al., International ... Assessment of Recovery Time, Worsening and Death, among COVID-19 i... 80% lower mortality (p<0.0001), 20% lower progression (p=0.43), and 31% faster viral clearance (p=0.26). Retr...



Opdam et al., Clinical Pharma... Identification of Risk Factors for COVID-19 Hospitalization in Patients wit... 45% lower hospitalization (*p*=0.18). Retrospective 81 cases and 396 controls among rheumatic disease patien...



Hall et al., The Annals of Thor... Multi-institutional Analysis of 505 COVID-19 Patients Supported with EC... 11% lower mortality (p=0.31). Retrospective 505 ECMO patients showing no significant difference in mortality i...



Ugarte-Gil et al., Annals of th... Characteristics associated with poor COVID-19 outcomes in individuals ... 44% lower severe cases (p=0.007). Retrospective 1,606 SLE patients showing lower risk of severe COVID-19 o...



Beaumont et al., Infectious Di... Factors associated with hospital admission and adverse outcome for CO... 14% lower combined mortality/intubation (p=0.55). Retrospective 296 hospitalized patients in France, showing...



Albanghali et al., Journal of In... Clinical Characteristics and Treatment Outcomes of Mild to Moderate Co... 35% higher mortality (p=0.46). Retrospective 811 hospitalized COVID+ patients in Saudi Arabia, showing highe...



Fernández-Cruz et al., Clinical... Higher mortality of hospitalized haematologic patients with COVID-19 co... 27% lower mortality (p=0.47). Retrospective 71 hospitalized haematologic patients in Spain, showing lower m...



Omma et al., The Journal of I... Hydroxychloroquine shortened hospital stay and reduced intensive care ... 28% lower mortality (p=0.3), 50% lower ICU admission (p=0.004), and 17% shorter hospitalization (p=0.007). R...



Erden et al., Bratislava Medic... COVID-19 outcomes in patients with antiphospholipid syndrome: a retro... 75% lower hospitalization (p=0.23). Retrospective 9 COVID-19 patients with antiphospholipid syndrome in Turk...



Lavilla Olleros et al., PLOS ON... Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish ... 36% lower mortality (p<0.0001). Retrospective 14,921 hospitalized patients in Spain, showing lower mortality ...



Alwafi et al., Cureus, doi:10.7... Negative Nasopharyngeal SARS-CoV-2 PCR Conversion in Response to ... 15% improved viral clearance (p=0.65). Retrospective 93 hospitalized patients in Saudi Arabia, 45 treated with ...



Tu et al., Infectious Diseases ... Risk Factors for Severity and Mortality in Adult Patients Confirmed with C... 17% lower mortality (p=0.81). Retrospective 180 hospitalized COVID-19 patients in Sierra Leone, showing no si...



Tyson et al., Preprint Low Rates of Hospitalization and Death in 4,376 COVID-19 Patients Give... 100% lower mortality (p<0.0001) and 100% lower hospitalization (p<0.0001). Retrospective 4,376 patients wit...



AbdelGhaffar et al., PLOS ON... Prediction of mortality in hospitalized Egyptian patients with Coronavirus... 100% lower mortality (p<0.0001). Retrospective 3,712 hospitalized patients in Egypt, showing lower mortality ...



Juneja et al., Journal of Basic ... Hydroxychloroquine pre-exposure prophylaxis provides no protection ag... 142% higher severe cases (p=0.59) and 6% more cases (p=0.67). Retrospective 2,200 healthcare workers in In...



Pineda et al., NCT04954040 Prevention and Treatment With Hydroxychloroquine + Azithromycin of Ac... Estimated 132 patient HCQ early treatment RCT with results not reported over 1.5 years after estimated compl...



Aston et al., NCT04334382 Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID... Estimated 1,550 patient HCQ early treatment RCT with results not reported over 1.5 years after estimated com...



Al Ansari et al., NCT04437693 Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 ... Estimated 500 participant HCQ prophylaxis RCT with results not reported over 1.5 years after estimated compl...

McKinnon et al., International ... Safety and Tolerability of Hydroxychloroquine in healthcare workers and ...

2% fewer symptomatic cases (p=1) and 51% fewer cases (p=0.6). HCQ prophylaxis RCT with 201 weekly HCQ ...



Rao et al., Expert Review of A... Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infec... 11% fewer cases (p=0.68). Prospective PrEP study with low risk healthcare workers in India showing RR=0.89 [...



Ferreira et al., Revista da Ass... Outcomes associated with Hydroxychloroquine and Ivermectin in hospit... 151% higher mortality (p=0.03) and 46% higher combined mortality/intubation (p=0.23). Retrospective 230 ho...



Calderón et al., PAMJ - Clinic... Treatment with hydroxychloroquine vs nitazoxanide in patients with COVI... 215% higher mortality (p=0.38), 652% higher ventilation (p=0.15), 145% higher ICU admission (p<0.0001), and ...



Ahmed et al., BioMed Resear... Factors Affecting the Incidence, Progression, and Severity of COVID-19 i... 99% fewer cases (p=0.08). Retrospective type 1 diabetes patients in Saudi Arabia showing reduced risk of case...



Samajdar et al., Journal of th... Ivermectin and Hydroxychloroquine for Chemo-Prophylaxis of COVID-19:... 75% fewer cases (p<0.0001). Physician survey in India with 164 ivermectin prophylaxis, 129 HCQ prophylaxis, ...



Schmidt et al., JAMA Network... Association Between Androgen Deprivation Therapy and Mortality Amon... 333% higher mortality (p=0.0001) and 613% higher severe cases (p<0.0001). Retrospective 1,106 prostate can...



Cortez et al., Western Pacific ... Clinical characteristics and outcomes of COVID-19 patients in a tertiary ... 15% lower mortality (*p*=1). Retrospective 280 hospitalized patients in the Philippines, 25 treated with HCQ, not...



Chechter et al., Heliyon, doi:1... Evaluation of patients treated by telemedicine in the beginning of the CO... 95% lower hospitalization (p=0.004). Prospective study of 187 telemedicine patients in Brazil. 74 presenting wi...



Sarhan et al., Journal of Infect... Efficacy of the early treatment with tocilizumab-hydroxychloroquine and ... 26% lower mortality (p=0.39), 26% higher hospital discharge (p=0.39), and 25% longer hospitalization (p=0.06)...



Perrella et al., Viruses, doi:10.... Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent CO... 71% higher ventilation (p=0.28), 33% higher ARDS (p=0.7), and 476% more cases (p<0.0001). Retrospective 8,...



González et al., Trials, doi:10.... Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infecti...
129 participant HCQ early treatment and prophylaxis RCT with results not reported over 1.5 years after comple...



Shousha et al., World Journal ... Hepatic and gastrointestinal disturbances in Egyptian patients infected ... 12% lower mortality (p=0.87). Retrospective 547 hospitalized COVID+ patients in Egypt, showing no significant ...



Guglielmetti et al., Scientific R... Treatment for COVID-19—a cohort study from Northern Italy 28% lower mortality (p=0.1). Retrospective 600 hospitalized patients in Italy, showing lower mortality with HCQ...

https://c19hcq.org 11/49



Belmont et al., ClinicalTrials.g... COVID-19 PrEP HCW HCQ Study

79% fewer symptomatic cases (p=0.21). Prospective study of HCQ prophylaxis in the USA, with 56 HCQ patien...



Atipornwanich et al., SSRN El... Various Combinations of Favipiravir, Lopinavir-Ritonavir, Darunavir-Riton... 56% lower mortality (p=0.07), 54% lower progression (p=0.02), and 7% faster viral clearance (p=0.51). RCT 32...



Fung et al., PLoS ONE, doi:10.... Effect of common maintenance drugs on the risk and severity of COVID-... 13% lower mortality (p=0.15), 3% lower hospitalization (p=0.63), and 9% fewer cases (p=0.02). Retrospective d...



Babalola et al., Journal of Infe... A Randomized Controlled Trial of Ivermectin Monotherapy Versus Hydrox... 55% lower hospital discharge (p=0.2) and 10% improved viral clearance (p=0.78). Small RCT with 61 patients i...



Nanni et al., Trials, doi:10.118... PROTECT Trial: A cluster-randomized study with hydroxychloroquine vers... Estimated 2,300 participant HCQ early treatment and prophylaxis RCT with results not reported over 2 years af...



Panda et al., Clinical Pharmac... Antiviral Combination Clinically Better Than Standard Therapy in Severe ... 48% lower mortality (p=0.45). RCT 111 patients in India in 5 groups: severe patients: A) standard treatment, B) ...



Menardi et al., PharmAdvanc... A retrospective analysis on pharmacological approaches to COVID-19 pa... 35% lower mortality (p=0.12). Retrospective 277 hospitalized patients in Italy, showing lower mortality with HC...



Uygen et al., Northern Clinics ... Effect of Hydroxychloroquine Use on the Length Of Hospital Stay in Child... 12% faster viral clearance (p=0.05). Retrospective 40 pediatric hospitalized patients, 15 treated with HCQ, sho...



Çivriz Bozdağ et al., Turk. J. H... Clinical Characteristics and Outcome of COVID-19 in Turkish Hematologi... 399% higher mortality (p=0.003). Retrospective 340 patients with hematological malignancy in Turkey, showin...



Alotaibi et al., International Jo... Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine ... 134% higher mortality (p=0.05). Retrospective hospitalized patients in Saudi Arabia, showing lower mortality w...



Agarwal et al., medRxiv, doi:1... Low dose hydroxychloroquine prophylaxis for COVID-19 - a prospective s... 27% lower progression (p=0.21) and 5% more cases (p=0.81). Small prophylaxis trial with 29 low dose HCQ an...



Accinelli et al., Travel Medicin... Hydroxychloroquine / azithromycin in COVID-19: The association betwee... Retrospective 1,265 outpatients in Peru treated with HCQ+AZ showing mortality associated with treatment del...



Sawanpanyalert et al., Southe... Assessment of outcomes following implementation of antiviral treatment... 42% lower progression (p=0.37). Retrospective 744 hospitalized patients in Thailand, showing lower risk of a p...



Karruli et al., Microbial Drug R... Multidrug-Resistant Infections and Outcome of Critically III Patients with ...

5% lower mortality (p=1). Retrospective 32 ICU patients, showing no significant difference with HCQ treatment...



Cordtz et al., Journal of Clinic... Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus E... 40% lower hospitalization (*p*=0.39). Retrospective 2,533 SLE patients in Denmark showing no significant differ...



Rodrigues et al., International ... Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 ... 14% improved viral clearance (*p*=0.15). RCT 84 low risk patients, 42 treated with HCQ/AZ, showing no significa...



Naggie et al., International Jo... Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health ... 24% fewer symptomatic cases (p=0.18). HCQ prophylaxis RCT reporting statistically significant lower cases wh...



Patil et al., Research Square, ... A Prospective Longitudinal Study Evaluating The Influence of Immunosu... 66% lower mortality (p=0.1) and 9% fewer cases (p=0.43). Prospective study of 9,212 autoimmune rheumatic ...



Navya et al., Informatics in M... A computational study on hydroxychloroquine binding to target proteins ... In Silico analysis showing that HCQ binds to multiple targets related to SARS-CoV-2 infection, including the AC...



McCullough et al., NCT04333... Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcar... 52% fewer cases (p=0.01). Prospective study with 221 healthcare workers, showing lower risk of COVID-19 wit...



Eldeen et al., Microbes and In... Comparative study between the therapeutic effect of remdesivir versus h... Small study comparing 25 HCQ and 25 remdesivir hospitalized patients, reporting faster viral clearance with re...



Tai et al., Pharmaceutics, doi:... Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment ... Analysis of HCQ solutions suitable for nebulization for COVID-19.



Shabani et al., Pulmonary Pha... Evaluation of the Prophylactic Effect of Hydroxychloroquine on People in ... 19% fewer symptomatic cases (p=1) and 6% more cases (p=1). Small PEP trial with 51 HCQ patients, not sho...



Stricker et al., Journal of Infec... Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcar... 75% lower mortality (p<0.0001). Meta analysis of 11 HCQ PrEP studies in India covering 7,616 healthcare work...



Özuygur Ermiş et al., Turkish ... The Efficacy of Hydroxychloroquine and Azithromycin Combination Ther... Retrospective 370 hospitalized patients, 222 receiving HCQ+AZ and 148 receiving HCQ, showing mortality OR ...



Bhatt et al., medRxiv, doi:10.1... Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practic... 49% more cases (p=0.02). Observational study of 927 low-risk healthcare workers in India, 731 volunteering fo...



Alghamdi et al., Saudi Pharm... Clinical characteristics and treatment outcomes of severe (ICU) COVID-1... 39% higher mortality (p=0.52). Retrospective 171 ICU patients in Saudi Arabia showing no significant differenc...

https://c19hcq.org 13/49



Barra et al., medRxiv, doi:10.1... COVID-19 in hospitalized patients in 4 hospitals in San Isidro, Buenos Air... 11% lower mortality (p=1). Retrospective 668 hospitalized patients in Argentina, 18 treated with HCQ, not sho...



Sobngwi et al., medRxiv, doi:1... Doxycycline is a safe alternative to Hydroxychloroquine + Azithromycin to... 52% improved recovery (p=0.44) and 3% improved viral clearance (p=0.88). RCT 194 mild/asymptomatic low-ri...



Küçükakkaş et al., Research S... The effect of hydroxychloroquine against SARS-CoV-2 infection in rheum... 43% higher ICU admission (p=1). Retrospective 17 rheumatoid arthritis COVID-19+ patients, 7 on HCQ treatme...



Alhamlan et al., medRxiv, doi:... Epidemiology and Clinical Characteristics in Individuals with Confirmed S... 52% higher mortality (p=0.58). Retrospective hospitalized patients in Saudi Arabia showing higher mortality wit...



Barrat-Due et al., Annals of Int... Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral ... 120% higher mortality (p=0.35). Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no sig...



Tamura et al., Diabetology & ... Outcome and death risk of diabetes patients with Covid-19 receiving pre... 299% higher mortality (p=0.04). Retrospective 188 hospitalized patients in Brazil, showing higher risk of mortal...



Arabi et al., Intensive Care Me... Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with C... 44% higher mortality (p=0.01). Very late stage RCT with 50 ICU patients treated with HCQ, 255 lopinavir-ritona...



Roger et al., Anaesthesia Criti... French Multicentre Observational Study on SARS-CoV-2 infections Intens... no change in mortality (p=0.94). Prospective study of 966 ICU patients in France, 289 treated with HCQ, showi...



Jacobs et al., The Annals of T... Multi-institutional Analysis of 200 COVID-19 Patients treated with ECMO:... 7% lower mortality (p=0.74). Prospective study of 200 ECMO patients showing no significant difference in una...



Shaw et al., Journal of Drugs i... COVID-19 in Individuals Treated With Long-Term Hydroxychloroquine: A ... 13% fewer cases (p=0.006). PSM retrospective 144 alopecia patients in the USA, showing lower risk of COVID-...



Granados-Montiel et al., BMJ ... New prophylaxis regimen for SARS-CoV-2 infection in health professiona... Estimated 214 participant HCQ + bromhexine prophylaxis RCT with results not reported over 2 years after esti...



Taieb et al., J. Clin. Med. 202... Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patient... 39% higher hospital discharge (p=0.02). Retrospective 926 patients in Senegal, 674 treated with HCQ+AZ, sho...



Gerlovin et al., American Jour... Pharmacoepidemiology, Machine Learning and COVID-19: An intent-to-t... 22% higher mortality (p=0.18) and 55% higher ventilation (p=0.02). Retrospective 1,769 hospitalized patients i...

Yadav et al., Research Square... Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine an...

In Silico study showing stronger inhibition of SAR-CoV-2 for HCQ+favipiravir+oseltamivir compared to any of th...



Schwartz et al., CMAJ Open, ... Assessing the efficacy and safety of hydroxychloroquine as outpatient tr... 37% improved recovery (p=0.15). Small early terminated late treatment RCT showing no significant differences....



Purwati et al., PLOS One, doi:... An in vitro study of dual drug combinations of anti-viral agents, antibiotic... In Vitro study of combinations of drugs showing antiviral efficacy of HCQ alone and in combination with AZ, fa...



Turrini et al., Vaccines, 10.33... Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients ... 10% lower mortality (p=0.15). Retrospective 205 patients in Italy, 160 treated with HCQ, showing lower mortali...



Saib et al., PLOS ONE, doi:10.... Lack of efficacy of hydroxychloroquine and azithromycin in patients hosp... 125% higher combined mortality/intubation (p=0.23). 203 hospitalized patients in France, not showing signific...



Singh et al., medRxiv, doi:0.1... Safety and efficacy of antiviral therapy alone or in combination in COVID-... 48% lower mortality (p=0.45) and 14% improved recovery (p=0.76). Very small early terminated RCT in India, sh...



Badyal et al., Journal of the A... Hydroxychloroquine for SARS CoV2 Prophylaxis in Healthcare Workers – ... 60% fewer cases (p<0.0001). Prophylaxis study with 12,089 Indian healthcare workers, showing lower risk of C...



Lagier et al., Therapeutics an... Outcomes of 2,111 COVID-19 hospitalised patients treated with 2 hydrox... 32% lower mortality (p=0.004). Retrospective 2,011 hospitalized patients in France, median age 67, showing lo...



Byakika-Kibwika et al., Resear... Safety and Efficacy of Hydroxychloroquine for Treatment of Non-Severe ... no change in recovery (p=0.91) and 29% improved viral clearance (p=0.47). Small 105 patient RCT in Uganda s...



Sivapalan et al., European Re... Azithromycin and hydroxychloroquine in hospitalised patients with confir... 92% lower mortality (p=0.32), 22% higher ICU admission (p=1), and 8% lower hospital discharge (p=0.36). Earl...



Kara et al., NCT04411433 Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatme... 1,008 patient HCQ early treatment RCT with results not reported over 2 years after completion.



Chauffe et al., NCT04363450 Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (... Estimated 1,700 participant HCQ prophylaxis RCT with results not reported over 2 years after estimated compl...



Korkmaz et al., Authorea, doi:... The effect of Hydroxychloroquine use due to rheumatic disease on the ri... 82% lower mortality (p=0.19) and 94% fewer cases (p<0.0001). Retrospective 683 patients in a rheumatology d...



Kamstrup et al., International ... Hydroxychloroquine as a primary prophylactic agent against sars-cov-2 i... 44% higher hospitalization (p=0.25) and 10% fewer cases (p=0.23). Retrospective HCQ users in Denmark, not ...



Ramírez-García et al., Archivo... Hydroxychloroquine and Tocilizumab in the Treatment of COVID-19: A Lo... 67% lower mortality (p<0.0001) and 6% higher ICU admission (p=1). Retrospective 403 hospitalized patients in...



Smith et al., medRxiv, doi:10.... Observational Study on 255 Mechanically Ventilated Covid Patients at th... 27% lower mortality (p=0.002). Retrospective 255 mechanical ventilation patients in USA, showing that weight-...



Ali et al., Journal of Pharmace... Optimizing the Use of Hydroxychloroquine in the Management of COVID-... Review of the mechanisms of action, pharmacokinetics and toxicity of HCQ, recommending use as early as po...



Million et al., Reviews in Cardi... Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 CO... 83% lower mortality (p=0.0007), 44% lower ICU admission (p=0.18), and 4% lower hospitalization (p=0.77). Ret...



Syed et al., Cureus, doi:10.77... Pre-exposure Prophylaxis With Various Doses of Hydroxychloroquine Am... 60% more symptomatic cases (p=0.41) and 92% more cases (p=0.12). Small PrEP RCT of low risk healthcare w...



Rojas-Serrano et al., PLOS O... Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A ran... 82% fewer symptomatic cases (p=0.12). Early terminated HCQ PrEP RCT with 62 HCQ and 65 placebo patients...



Drancourt et al., Viruses, doi:... SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroqu... Retrospective 3,737 patients in France, showing lower risk of persistent viral shedding with HCQ+AZ treatment.



Sammartino et al., PLOS One,... Predictors for inpatient mortality during the first wave of the SARS-CoV-2... 240% higher mortality (p=0.002). Retrospective 1,108 hospitalized patients in New York showing significantly h...



Vigbedor et al., Journal of Ap... Review of four major biomolecular target sites for COVID-19 and possibl... Review of major target sites in SARS-CoV-2 and the host organism along with potential inhibitors.



De Rosa et al., J. Clin. Med., d... Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont,... 35% lower mortality (p=0.02). Retrospective 1,538 hospitalized patients in Italy, showing only HCQ associated ...



Moraes et al., NCT04384458 Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 P... Estimated 400 participant HCQ vs. ivermectin prophylaxis RCT with results not reported over 2 years after esti...



Borrie et al., NCT04397328 COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care -...
Estimated 336 participant HCQ prophylaxis RCT with results not reported over 2 years after estimated complet...



James et al., NCT04352933 PROLIFIC ChemoprophylaxisTrial (COVID-19)
Estimated 500 participant HCQ prophylaxis RCT with results not reported over 2 years after estimated complet...

Çiyiltepe et al., South. Clin. Ist... The Effect of Pre-admission Hydroxychloroquine Treatment on COVID-19...

3% lower mortality (p=0.85). Retrospective 147 ICU patients in Turkey, showing no significant difference in out...



Bosaeed et al., Infect. Dis. Th... Favipiravir and Hydroxychloroquine Combination Therapy in Patients wit... 4% lower mortality (p=0.91), 8% higher ventilation (p=0.78), 31% higher ICU admission (p=0.24), and 29% slo...



Haji Aghajani et al., Journal o... Decreased in-hospital mortality associated with aspirin administration in... 19% lower mortality (p=0.09). Retrospective 991 hospitalized patients in Iran, showing lower mortality with HC...



Aghajani et al., Journal of Me... Decreased In-Hospital Mortality Associated with Aspirin Administration i... 19% lower mortality (p=0.09). Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also s...



Kokturk et al., Respiratory Me... The predictors of COVID-19 mortality in a nationwide cohort of Turkish p... 4% higher mortality (p=0.97). Retrospective 1,500 hospitalized late stage (median SaO₂ 87.7) patients in Turke...



Réa-Neto et al., Scientific Rep... An open-label randomized controlled trial evaluating the efficacy of chlor... 57% higher mortality (p=0.2), 115% higher ventilation (p=0.03), and 147% worse recovery (p=0.02). Early termi...



Mohandas et al., Clinical review of COVID-19 patients presenting to a quaternary care priv... 81% higher mortality (p=0.007). Retrospective 3,345 hospitalized patients in India, 11.5% treated with HCQ, sh...



Corradini et al., Internal and E... Clinical factors associated with death in 3044 COVID-19 patients manag... 70% lower mortality (p<0.0001). Retrospective 3,044 hospitalized COVID-19 patients in Italy, showing HCQ sig...



Toya et al., SSRN A Cross-Country Analysis of the Determinants of COVID-19 Fatalities Country based analysis finding lower mortality with the use of HCQ.



Reis et al., JAMA Network Op... Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Riton... 24% lower hospitalization (p=0.57) and 4% improved viral clearance (p=0.1). Early terminated RCT in Brazil sho...



Alzahrani et al., Rheumatolog... Clinical characteristics and outcome of COVID-19 in patients with rheum... 59% lower mortality (p=1), 81% lower ventilation (p=0.54), and 33% lower severe cases (p=0.7). Retrospective ...



Alegiani et al., Rheumatology,... Risk of COVID-19 hospitalization and mortality in rheumatic patients trea... 8% higher mortality (p=0.64) and 18% lower hospitalization (p=0.03). Retrospective database analysis case co...



Seet et al., International Jour... Positive impact of oral hydroxychloroquine and povidone-iodine throat s... 35% fewer symptomatic cases (p=0.05) and 32% fewer cases (p=0.009). Prophylaxis RCT in Singapore with 3,0...



Gadhiya et al., BMJ Open, doi... Clinical characteristics of hospitalised patients with COVID-19 and the i... 5% higher mortality (p=0.89). Retrospective 283 patients in the USA showing higher mortality with all treatmen...



Mulhem et al., BMJ Open, doi... 3219 hospitalised patients with COVID-19 in Southeast Michigan: a retro... 28% higher mortality (p=0.1). Retrospective database analysis of 3,219 hospitalized patients in the USA. Very d...



Mokhtari et al., International I... Clinical outcomes of patients with mild COVID-19 following treatment wi... 70% lower mortality (p<0.0001) and 35% lower hospitalization (p<0.0001). Retrospective 28,759 adult outpatie...



Edington et al., European Jou... Safety of treatment with chloroquine and hydroxychloroquine: A ten-year... Safety analysis of CQ and HCQ covering 46 RCTs with 23,132 patients, showing no mortality attributed to CQ/...



Morales-Asencio et al., NCTO... Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis... Estimated 1,930 participant HCQ prophylaxis nursing home RCT with results not reported over 2 years after es...



Alghamdi et al., Antibiotics, d... Clinical Efficacy of Hydroxychloroguine in Patients with COVID-19: Findin... 7% higher mortality (p=0.88). Retrospective 775 hospitalized patients in Saudi Arabia showing no significant di...



Safety of hydroxychloroguine in healthcare workers for COVID-19 prophy... Faruqui et al., Indian J. Med. ... Retrospective 1303 health care workers finding that HCQ prophylaxis was well tolerated. 20% reported an adv...



Dev et al., Transactions of The... Risk factors and frequency of COVID-19 among healthcare workers at a t... 26% fewer cases (p=0.003). Retrospective case control study of 3,100 healthcare workers in India showing low...



Barry et al., International Jour... Clinical Characteristics and Outcomes of Hospitalized COVID-19 Patient... 99% lower mortality (p=0.6). 605 hospitalized patients in Saudi Arabia showing no mortality with HCQ (only 6 ...



Stewart et al., PLoS ONE, doi.... COVID-19 Evidence Accelerator: A parallel analysis to describe the use of... 18% higher mortality (p=0.27) and 29% higher ventilation (p=0.09). Collection of seven retrospective database ...



Dang et al., bioRxiv, doi:10.11... Structural basis of anti-SARS-CoV-2 activity of hydroxychloroguine: speci... Microscopy/spectroscopy study showing that HCQ binds to both N-terminal domain and C-terminal domain of ...



Roy et al., medRxiv, doi:10.11... Outcome of Different Therapeutic Interventions in Mild COVID-19 Patient... 2% faster recovery (p=0.96). Retrospective database analysis of 56 mild COVID-19 patients, all treated with vita...



Vivanco-Hidalgo et al., Euros... Incidence of COVID-19 in patients exposed to chloroquine and hydroxyc... 46% higher hospitalization (p=0.1) and 8% more cases (p=0.5). Retrospective database analysis of chronic HC...



Martin-Vicente et al., medRxiv... Absent or insufficient anti-SARS-CoV-2 S antibodies at ICU admission ar... 59% lower mortality (p=0.41). Retrospective 92 ICU patients with almost all treated with HCQ and only one non...



Salvador et al., Cureus, doi:10... Clinical Features and Prognostic Factors of 245 Portuguese Patients Hos...

33% lower mortality (p=0.1), 448% higher ventilation (p=0.003), and 17% lower combined mortality/intubation...



Rubio-Sánchez et al., Advanc... Prognostic factors for the severity of SARS-CoV-2 infection 40% lower severe cases (p=0.02). Retrospective 197 hospitalized COVID-19 patients in Spain, showing lower p...



Pham et al., Rheumatology A... Failure of chronic hydroxychloroquine in preventing severe complications... 20% lower mortality (*p*=0.77) and 35% higher ICU admission (*p*=0.61). Tiny retrospective database analysis of ...



Thakar et al., Indian J. Med. R... Chloroquine nasal drops in asymptomatic & mild COVID-19: An explorat... Small RCT for CQ nasal drops suggesting efficacy in preventing infection, while no significant difference was s...



Bhandari et al., International J... A Preventive Study on Hydroxychloroquine Prophylaxis against COVID-19... Retrospective 4,239 healthcare workers using HCQ prophylaxis showing no mortality, 8 mild symptomatic cas...



Shang et al., Virology Journal,... Inhibitors of endosomal acidification suppress SARS-CoV-2 replication a... In Vitro study showing that endosomal acidification inhibitors including chloroquine reduce SARS-CoV-2 replic...



Mordmüller et al., NCT04342... Hydroxychloroquine for COVID-19 (COV-HCQ)
30 patient HCQ late treatment RCT with results not reported over 2.5 years after completion.



Amaravadi et al., medRxiv, doi... Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at ho... 60% improved recovery (p=0.13). Tiny early-terminated 34 patient RCT for outpatient treatment showing faster ...



Tanriverdi et al., Turkish Journ... Hydroxychloroquine plus azithromycin and early hospital admission are ... Retrospective 83 hospitalized patients in Turkey confirming that earlier treatment is better, and showing that th...



Giraud-Gatineau et al., Resear... The Need for Early Management in Patients With COVID-19

Review of early treatment of COVID-19 at IHU Méditerranée Infection in France, including HCQ+AZ treatment, c...



Beltran Gonzalez et al., Infecti... Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients wit... 63% lower mortality (p=0.27) and 25% lower progression (p=0.57). RCT late stage severe condition (93% SOFA...




Bae et al., Viruses 2021, doi:1... Recent Hydroxychloroquine Use Is Not Significantly Associated with Posi... 30% fewer cases (p=0.18). Retrospective database analysis of prior HCQ usage in South Korea, showing non-s...



Lamback et al., The Brazilian ... Hydroxychloroquine with azithromycin in patients hospitalized for mild a... 9% lower mortality (p=0.83), 20% higher ICU admission (p=0.61), and 12% shorter hospitalization. Retrospecti...



Awad et al., American Journal... Impact of hydroxychloroquine on disease progression and ICU admissio... 19% higher mortality (p=0.6), 461% higher ventilation (p<0.0001), and 463% higher ICU admission (p<0.0001). ...



16% lower mortality (p=0.76). Retrospective 79 hospitalized nonagenarian patients showing unadjusted HCQ ...



Di Castelnuovo et al., Journal ... Disentangling the Association of Hydroxychloroquine Treatment with Mo... 40% lower mortality (p<0.0001). Retrospective 4,396 hospitalized patients in Italy showing significantly lower ...



Strangfeld et al., Annals of the... Factors associated with COVID-19-related death in people with rheumati... 48% lower mortality (p<0.0001). Retrospective 3,729 rheumatic disease patients showing lower risk of mortalit...



Trefond et al., Revue du Rhum... Effet d'un traitement par hydroxychloroquine prescrit comme traitement ... 17% higher mortality (p=0.8), 78% higher combined mortality/ICU admission (p=0.21), and 45% higher hospit...



Eftekhar et al., medRxiv, doi:1... Hydroxychloroquine and azithromycin: As a double edge sword for COVI... Retrospective 172 hospitalized patients, 83% treated and HCQ+AZ and 17% with HCQ, not finding a significan...



Dabbous et al., Archives of Vir... Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized ... This study was retracted.



Hussein et al., Journal of Mol... Molecular Docking Identification for the efficacy of Some Zinc Complexe...

Molecular dynamics analysis recommending Zn (CQ) Cl2(H2O) and Zn (HCQ) Cl2(H2O) as potential inhibitors f...



Zelenko, Z., Preprint Nebulized Hydroxychloroquine for COVID-19 Treatment: 80x Improveme...

Report on the use of nebulized HCQ showing much more rapid improvement compared to tablets, with 95% of...



Cifuentes et al., Medicina Clín... Incidence of COVID-19 in patients under chronic treatment with hydroxy... Retrospective 3,817 chronic HCQ patients showing 4.4% COVID-19 positive rate, 1.3% severe. There is no co...



Li et al., Science China Life Sc... Evaluation of the efficacy and safety of hydroxychloroquine in compariso... 50% higher hospital discharge (p=0.09). Small RCT comparing HCQ and CQ in China with 88 very late stage (1...



Khoubnasabjafari et al., Post... Prevalence of COVID-19 in patients with rheumatoid arthritis (RA) alread... 17% fewer cases (p=0.59). Survey analysis of 1,858 RA patients in Iran, showing no significant difference in ca...



Li et al., Research Square, doi... Treatment of COVID-19 patients with hydroxychloroquine or chloroquine:... 40% slower viral clearance (p=0.06). Small retrospective database analysis of 37 late stage patients hospitalize...




Rangel et al., Journal of the A... Chronic Hydroxychloroquine Therapy and COVID-19 Outcomes: A Retros... 25% lower mortality (p=0.77) and 22% lower hospitalization (p=0.29). Retrospective 50 COVID-19 patients that...



Yegerov et al., medRxiv, doi:1... Epidemiological and Clinical Characteristics, and Virologic Features of C... 95% lower mortality (p=1). Retrospective 1,072 hospitalized patients in Kazakhstan showing no mortality for H...

https://c19hcq.org 21/49



Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbidities, showing 2.2% hospitali...



Güner et al., Journal of Infecti... Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Tr... 77% lower ICU admission (p=0.16). Retrospective 824 hospitalized patients in Turkey showing lower ICU admi...



Cordtz et al., Rheumatology, ... Incidence and severeness of COVID-19 hospitalisation in patients with in... Retrospective 58,052 rheumatic disease patients in Denmark showing that RA patients have a higher risk of C...



Chari et al., Blood, doi:10.118... Clinical features associated with COVID-19 outcome in multiple myelom... 33% lower mortality (p=0.17). Retrospective multiple myeloma patients showing lower mortality with HCQ trea...



Su et al., BioScience Trends, ... Efficacy of early hydroxychloroquine treatment in preventing COVID-19 p... 85% lower progression (*p*=0.006), 24% faster improvement (*p*=0.02), and 36% improved viral clearance (*p*=0.0...



Taccone et al., The Lancet Re... The role of organizational characteristics on the outcome of COVID-19 p... 25% lower mortality (p=0.02). Retrospective 1,747 ICU patients in Belgium showing lower mortality with HCQ, ...



Cangiano et al., Aging, doi:10... Mortality in an Italian nursing home during COVID-19 pandemic: correlati... 73% lower mortality (p=0.03). 73% lower mortality with HCQ. Analysis of 98 PCR+ nursing home residents in It...



Huh et al., International Journ... Association of prescribed medications with the risk of COVID-19 infectio... 251% higher progression (p=0.11) and 6% fewer cases (p=0.82). Retrospective database analysis with 17 case...



Matangila et al., PLoS ONE, d... Clinical characteristics of COVID-19 patients hospitalized at Clinique Ng... 55% lower mortality (p=0.21). 55% lower death with HCQ+AZ. Retrospective 160 hospitalized patients in the D...



Signes-Costa et al., Archivos ... Prevalence and 30-day mortality in hospitalized patients with COVID-19 ... 47% lower mortality (p=0.0005). 47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung dis...



Gönenli et al., Infectious Dise... Analysis of the Prophylactic use of Hydroxychloroquine at the Beginning ... 30% lower progression (p=0.77) and 19% more cases (p=0.58). Small prophylaxis survey showing lower, but n...




De Luna et al., medRxiv, doi:1... Clinical and Demographic Characteristics of COVID-19 Patients Admitte... 105% higher mortality (p=0.69). Retrospective 150 patients in the Dominican Republic, 132 treated with HCQ, ...



Sofian et al., Wiener Medizinis... SARS-CoV-2, a virus with many faces: a series of cases with prolonged p... Report on a series of 10 patients experiencing prolonged COVID-19 symptoms that were given HCQ 250mg bi...



Orioli et al., Diabetes & Metab... Clinical characteristics and short-term prognosis of in-patients with diab... 13% lower mortality (p=1). Small retrospective study of 73 diabetic patients in Belgium, 55 HCQ patients, sho...



27% more cases (p=0.33). Early terminated PEP RCT comparing HCQ and vitamin C with 781 low-risk patients ...



Ozturk et al., Nephrology Dial... Mortality analysis of COVID-19 infection in chronic kidney disease, haem... 44% lower mortality (p=0.14). Retrospective 1210 hospitalized patients in Turkey focused on chronic kidney dis...



Modrák et al., medRxiv, doi:1... Detailed disease progression of 213 patients hospitalized with Covid-19 i... 59% lower mortality (p=0.04). Retrospective 213 hospitalized patients in Czech Republic showing lower mortal...



Peng et al., Nephrology Dialys... Early versus late acute kidney injury among patients with COVID-19—a ... 11% lower progression (p=0.63). Retrospective 4020 hospitalized patients in China showing non-statistically si...



Wiseman et al., medRxiv, doi:... Effective post-exposure prophylaxis of Covid-19 is associated with use of... 42% fewer cases (p=0.04). 6th independent analysis showing efficacy from the Boulware PEP trial. This prospe...



Capsoni et al., Research Squa... CPAP Treatment In COVID-19 Patients: A Retrospective Observational St... 40% lower ventilation (p=0.3). Small 52 patient retrospective study of patients with acute respiratory failure sh...



Aboulenain et al., HCA Health... The Effect of Hydroxychloroquine on In-Hospital Mortality in COVID-19

15% higher mortality (p=0.72). Retrospective 175 hospitalized COVID-19 patients in the USA, showing no signi...



Abdulrahman et al., medRxiv, ... The efficacy and safety of hydroxychloroquine in COVID19 patients : a m... 17% lower mortality (p=1) and 75% higher combined mortality/intubation (p=0.24). Retrospective analysis of a...



Abd-Elsalam et al., Biological ... Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquin...

191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference. No infor...



Lambermont et al., Critical Ca... Predictors of Mortality and Effect of Drug Therapies in Mechanically Vent... 32% lower mortality (p=0.46). Retrospective 247 mechanically ventilated patients showing lower mortality with...



Ruiz et al., International Journ... Hydroxychloroquine lung pharmacokinetics in critically ill patients infecte... HCQ lung pharmacokinetic study confirming that lung concentrations can be much higher than plasma and ex...



Rodriguez-Gonzalez et al., Int... COVID-19 in hospitalized patients in Spain: a cohort study in Madrid 23% lower mortality (p=0.26). Retrospective 1255 patients in Spain showing lower mortality with HCQ. Subject...



van Halem et al., BMC Infect ... Risk factors for mortality in hospitalized patients with COVID-19 at the st... 32% lower mortality (p=0.05). Retrospective 319 hospitalized patients in Belgium showing lower mortality with ...



Burdick et al., Journal of Clini... Is Machine Learning a Better Way to IdentifyCOVID-19 Patients Who Mig... 59% higher mortality (p=0.12). 290 patient observational trial in the USA, not showing a significant difference ...

https://c19hcq.org 25/49



Abbas et al., Int. J. Clin. Pract.... Assessment of COVID-19 Treatment containing both Hydroxychloroquin... Prospective study of 161 hospitalized patients in Iraq showing HCQ+AZ appears to help recovery. Most mortali...



Qin et al., Thrombosis Resear... Low molecular weight heparin and 28-day mortality among patients with... 34% lower mortality (p=0.61). Low molecular weight heparin study also showing results for HCQ treatment, un...



Akram et al., Trials, doi:10.11... Pakistan Randomized and Observational Trial to Evaluate Coronavirus Tr... 550 patient HCQ early treatment RCT with results not reported over 2.5 years after completion.



Revollo et al., Journal of Anti... Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcar... 23% fewer cases (p=0.52). Retrospective PrEP analysis with 69 healthcare workers on PrEP HCQ, and 418 cont...



Omrani et al., EClinicalMedici... Randomized double-blinded placebo-controlled trial of hydroxychloroqui... 12% lower hospitalization (p=1), 26% improved recovery (p=0.58), and 10% worse viral clearance (p=0.13). Lo...



Falcone et al., Open Forum In... Role of low-molecular weight heparin in hospitalized patients with SARS-... 65% lower mortality (p=0.2). Prospective observational study of 315 hospitalized patients in Italy showing 65%...



Budhiraja et al., medRxiv, doi:... Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care H... 65% lower mortality (p<0.0001). Retrospective 976 hospitalized patients with 834 treated with HCQ+AZ showi...



Boari et al, Biosci. Rep., doi:1... Prognostic factors and predictors of outcome in patients with COVID-19 ... 55% lower mortality (*p*=0.001). Retrospective 258 hospitalized patients in Italy showing lower mortality with H...



Sheshah et al., Diabetes Rese... Prevalence of Diabetes, Management and Outcomes among Covid-19 A... 80% lower mortality (p=0.001). Retrospective 300 hospitalized patients in Saudi Arabia showing HCQ adjusted ...



Simova et al., New Microbes ... Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health ... 94% lower hospitalization (*p*=0.01) and 96% improved viral clearance (*p*=0.001). 100% reduction in hospitaliza...



Simova et al., New Microbes ... Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health ... 93% fewer cases (p=0.01). 100% reduction in cases with HCQ+zinc post-exposure prophylaxis. Brief report for ...



Tchounga et al., Journal of Ph... Composition analysis of falsified chloroquine phosphate samples seized ... Analysis of fake CQ tablets finding: - no CQ in six samples, substituted with metronidazole (at sub-therapeutic l...



Águila-Gordo et al., Revista E... Mortality and associated prognostic factors in elderly and very elderly ho... 67% lower mortality (p=0.1). 67% lower mortality with HCQ. Retrospective 416 elderly patients in Spain showin...



Khamis et al., International Jo... Randomized Controlled Open Label Trial on the Use of Favipiravir Combi...

Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 ...



Rodriguez et al., Medicina Int... Severe infection due to the SARS-CoV-2 coronavirus: Experience of a tert... 59% lower mortality (p=0.23). Small prospective study of 43 hospitalized patients with 39 taking HCQ, showin...



Self et al., JAMA, doi:10.1001... Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalize... 6% higher mortality (p=0.85) and 3% worse 7-point scale results (p=0.87). Early terminated very late stage (65...



Brown et al., Annals of the A... Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVI... Small early terminated very late stage (86% on oxygen, 44% enrolled in the ICU) RCT comparing HCQ vs. AZ, n...



Núñez-Gil et al., Intern. Emer... Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-... 8% lower mortality (p=0.005). Retrospective database study of 1,021 patients in Ecuador, Germany, Italy, and S...



Mathai et al., J. Marine Medic... Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in he... 90% fewer cases (p<0.0001). 90% reduction in cases with HCQ pre-exposure prophylaxis. Retrospective 604 h...



Datta et al., Journal of Vaccin... No Role of HCQ in COVID-19 Prophylaxis: A Survey amongst Indian Doct... 22% fewer cases (p=0.47). Survey of Indian doctors not finding a significant effect of HCQ prophylaxis.



Dhibar et al., International Jo... Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Preve... 44% fewer symptomatic cases (p=0.21) and 50% fewer cases (p=0.04). Low dose prospective PEP study with 1...



Maldonado et al., Nefrología, ... COVID-19 incidence and outcomes in a home dialysis unit in Madrid (Sp... 91% lower mortality (p=0.17). Very small retrospective of 12 dialysis patients showing 1/11 deaths with HCQ a...



Rodriguez-Nava et al., Mayo ... Clinical characteristics and risk factors for mortality of hospitalized patie... 6% higher mortality (p=0.77). Retrospective 313 patients, mostly critical stage and mostly requiring respiratory...



Salazar et al., The American J... Significantly Decreased Mortality in a Large Cohort of Coronavirus Disea... 37% higher mortality (p=0.28). Convalescent plasma study also showing mortality based on HCQ treatment, u...




Cadegiani et al., New Microb... Early COVID-19 Therapy with azithromycin plus nitazoxanide, ivermectin ... 81% lower mortality (p=0.21), 95% lower ventilation (p=0.0008), and 98% lower hospitalization (p<0.0001). Co...



Behera et al., PLoS ONE, doi:... Role of ivermectin in the prevention of SARS-CoV-2 infection among heal... 28% fewer cases (p=0.29). Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vita...



López et al., Annals of Pediatr... Telemedicine follow-ups for COVID-19: experience in a tertiary hospital 64% lower progression (p=0.02). Retrospective 72 pediatric patients showing HCQ associated with a shorter d...



https://c19hcq.org 28/49

Mohana et al., International J... Hydroxychloroquine Safety Outcome within Approved Therapeutic Proto...

Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpatient setting...



Burney et al., NCT04370015 Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-ri... Estimated 374 participant HCQ prophylaxis RCT with results not reported over 2.5 years after estimated compl...



Guisado-Vasco Clinical characteristics and outcomes among hospitalized adults with se... 20% lower mortality (p=0.36). Retrospective 607 patients reporting results for early outpatient HCQ use with m...



SOLIDARITY Trial Consortium... Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial ... 19% higher mortality (p=0.23). WHO SOLIDARITY open-label trial with 954 very late stage (64% on oxygen/vent...



Annie et al., Pharmacotherapy... Hydroxychloroquine in hospitalized COVID-19 patients: Real world experi... 4% lower mortality (p=0.83). Retrospective database analysis with PSM not including COVID-19 severity, findin...



Sili et al., medRxiv, doi:10.110... Factors associated with progression to critical illness in 28 days among ... Analysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the incidence of c...



Aparisi et al., medRxiv, doi:10... Low-density lipoprotein cholesterol levels are associated with poor clinic... 63% lower mortality (p=0.008). Retrospective 654 hospitalized patients focused on low-density lipoprotein chol...



Soto-Becerra et al., medRxiv, ... Real-World Effectiveness of hydroxychloroquine, azithromycin, and iverm... 18% lower mortality (p<0.0001). Retrospective database study of 5683 patients, 692 received HCQ/CQ+AZ, 20...



Ader et al., medRxiv, doi:10.1... An open-label randomized, controlled trial of the effect of lopinavir/ritona... 15% higher mortality (p=0.7) and 24% improved viral clearance (p=0.68). Early terminated very late stage (95%...



Mori et al., Journal of Microbi... Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide fo... Small case study of 5 patients in Japan showing improvement with HCQ+AZ+ciclesonide.



Prodromos et al., New Microb... Hydroxychloroquine is effective, and consistently so used early, for Covid... Meta analysis of 43 studies reporting: "HCQ was found consistently effective against COVID-19 when used earl...



Nachega et al., The American... Clinical Characteristics and Outcomes of Patients Hospitalized for COVI... 28% lower mortality (p=0.17) and 26% greater improvement (p=0.13). Retrospective 766 hospitalized patients i...



Almazrou et al., Saudi Pharm... Comparing the impact of Hydroxychloroquine based regimens and stand... 65% lower ventilation (p=0.16) and 21% lower ICU admission (p=0.78). Retrospective 161 hospitalized patients...



Sow et al., NCT04501965 Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Az... 231 patient HCQ vs. phytomedicines early treatment RCT with results not reported over 2.5 years after comple...



Yadav et al., ResearchGate, d... Sero-survey for health-care workers provides corroborative evidence for t... 82% lower hospitalization (p=0.01) and 42% fewer cases (p=0.05). ICMR seroprevalence survey of 500 healthc...



Polat et al., Medical Journal o... Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 - ... 57% fewer cases (p=0.03). Small prophylaxis study of 208 healthcare workers in Turkey, 138 with high risk exp...



Ayerbe et al., Internal and Em... The association of treatment with hydroxychloroquine and hospital mort... 52% lower mortality (p=0.001). 2075 hospital patients in Spain showing HCQ reduces mortality 52%, odds rati...



Ladapo et al., medRxiv, doi:1... Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in... 24% lower combined death/hospitalization/cases (p=0.03). Meta analysis of prophylactic and early treatment ...



Abella et al., JAMA Internal M... Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure S... 5% fewer cases (p=1). Very small early-terminated underpowered PrEP RCT with 64/61 HCQ/control patients a...



Lammers et al., Int. J. Infectio... Early hydroxychloroquine but not chloroquine use reduces ICU admissio... 32% lower combined mortality/ICU admission (*p*=0.02). Observational study 1,064 hospitalized patients in the ...



Dabbous et al., Scientific Rep... Safety and efficacy of favipiravir versus hydroxychloroquine in managem... This paper has been retracted [nature.com].



Luco, J., Trends Med, doi:10.... Hydroxychloroquine as post-exposure prophylaxis for Covid-19: Why sim... Reanalysis of Boulware et al. PEP trial data showing statistically significant improvements with HCQ.



Gasperetti et al., EP Europace... Arrhythmic safety of hydroxychloroquine in COVID-19 patients from differ... Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for patients with ...



Shoaibi et al., medRxiv, doi:1... Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patie... 15% lower mortality (p=0.001). Retrospective database analysis focused on Famotidine but also showing resul...



Ulrich et al., Open Forum Infe... Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Dou... 6% higher mortality (p=1) and 173% higher ICU admission (p=0.13). Small RCT on very late stage use of HCQ, ...



Serrano et al., Ann. Oncol., 20... COVID-19 and lung cancer: What do we know?

43% lower mortality (p=0.15). Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, s...



Gentry et al., Lancet Rheumat... Long-term hydroxychloroquine use in patients with rheumatic conditions... 91% lower mortality (p=0.1) and 21% fewer cases (p=0.27). Retrospective patients with rheumatologic conditio...

Rajasingham et al., medRxiv, ... Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in health...

https://c19hcq.org 30/49

27% fewer cases (p=0.12). PrEP RCT showing HR 0.73, p = 0.12. Trial halted after 47% enrollment, p < 0.05 will...



Grau-Pujol et al., Trials, doi:10... Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a doub... 11% fewer cases (p=1). Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. There were no...



Lofgren et al., Open Forum Inf... Safety of Hydroxychloroquine among Outpatient Clinical Trial Participant... Analysis of 2,795 outpatients not showing significant safety concerns with HCQ. No deaths were related to HC...



Axfors et al., Nature, doi:10.1... Mortality outcomes with hydroxychloroquine and chloroquine in COVID-... Meta analysis assigning 89% weight to the RECOVERY and SOLIDARITY trials, producing the same result. Thes...



Karatza et al., Xenobiotica Optimization of hydroxychloroquine dosing scheme based on COVID-19 ...

Analysis of HCQ dosing, suggesting that high initial doses followed by low and sparse doses may offer signific...



Ashinyo et al., Pan African Me... Clinical characteristics, treatment regimen and duration of hospitalizatio... 33% shorter hospitalization (*p*=0.03). Retrospective 307 hospital patients in Ghana showing 33% reduction in ...



Lauriola et al., Clinical and Tra... Effect of combination therapy of hydroxychloroquine and azithromycin o... 74% lower mortality (p=0.001). Retrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted ...



Sulaiman et al., medRxiv, doi:... The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patie... 64% lower mortality (p=0.01) and 39% lower hospitalization (p=0.001). Observational prospective 5,541 patien...



Pellegrini et al., COVID-SHIEL... Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID... Estimated 2,250 participant HCQ prophylaxis RCT with results not reported over 2.5 years after estimated com...



Heberto et al., IJC Heart & Va... Implications of myocardial injury in Mexican hospitalized patients with c... 54% lower mortality (p=0.04) and 65% lower ventilation (p=0.008). Observational prospective 254 hospitalized ...



Alamdari et al., Tohoku J. Exp... Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major ... 55% lower mortality (p=0.03). Retrospective 459 patients in Iran with 93% treated with HCQ, showing HCQ mo...



Kirenga et al., BMJ Open Res... Characteristics and outcomes of admitted patients infected with SARS-C... 26% faster recovery (p=0.2). Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% faster...



Rentsch et al., The Lancet Rh... Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality:... 3% higher mortality (p=0.83). Observational database study of RA/SLE patients in the UK, 194,637 RA/SLE patien.



Laplana et al., PLOS ONE, doi... Lack of protective effect of chloroquine derivatives on COVID-19 disease ... 56% more cases (p=0.24). Survey of 319 autoimmune disease patients taking CQ/HCQ with 5.3% COVID-19 in...

https://c19hcq.org 31/49



IHU, Expert Review of Clinical ... Natural history and therapeutic options for COVID-19

Review of the current state of knowledge regarding the natural history of and therapeutic options for COVID-19...



Synolaki et al., medRxiv, doi:1... The Activin/Follistatin-axis is severely deregulated in COVID-19 and inde... 24% lower mortality (p=0.27). Retrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients. V...



Furtado et al., The Lancet, doi... Azithromycin in addition to standard of care versus standard of care alon... Small RCT comparing the addition of AZ for very late stage patients on ventilation or oxygen. No significant diff...



Wang et al., Phytomedicine, d... Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexi... In Vitro study providing novel insights into the molecular mechanism of CQ/HCQ treatment, showing that CQ a...



Heras et al., European Geriatri... COVID-19 mortality risk factors in older people in a long-term care center 96% lower mortality (p=0.004). Retrospective 100 COVID+ elderly nursing home patients, HCQ+AZ mortality 11...



de la Iglesia et al., medRxiv, d... Hydroxicloroquine for pre-exposure prophyylaxis for SARS-CoV-2 43% more cases (p=0.15). Analysis of autoimmune disease patients on HCQ, compared to a control group fro...



Hecel et al., Pharmaceuticals,... Zinc(II)—The Overlooked Éminence Grise of Chloroquine's Fight against ... Review of zinc as an inhibitor of SARS-CoV-2's RNA-dependent RNA polymerase, and zinc ionophores includin...



Elbazidi et al., New Microbes ... Pandemic and social changes, political fate

Analysis of US states and countries. Country analysis shows a significant correlation between the dates of deci...



Sarwar et al., NCT04346667 Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Pat...
125 participant HCQ prophylaxis RCT with results not reported over 3 years after completion.



Sarwar et al., NCT04351191 PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Usin...
137 patient HCQ early treatment RCT with results not reported over 3 years after completion.



Albani et al., J, Clinical Medici... Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality ... 18% lower mortality (p=0.15) and 9% higher ICU admission (p=0.7). Retrospective 1376 hospitalized patients i...



Castillo et al., Journal of Ster... Effect of calcifediol treatment and best available therapy versus best avai... RCT on calcifediol (25-hydroxyvitamin D) treatment for hospitalized COVID-19 patients showing significantly re...



Fried et al., Clinical Infectious ... Patient Characteristics and Outcomes of 11,721 Patients with COVID19 ... 27% higher mortality (p=0.001). Database analysis of 11,721 hospitalized patients, 4,232 on HCQ. Strong evid...

Ferri at al., Clinical Rheumatol... COVID-19 and rheumatic autoimmune systemic diseases: report of a lar...

https://c19hcq.org 32/49

63% fewer cases (p=0.02). Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HCQ e...



Fiolet et al., Clinical Microbiol... Effect of hydroxychloroquine with or without azithromycin on the mortalit... Meta analysis of late stage studies (and one early treatment study with only 2 deaths), showing HCQ RR 0.83 [...



Ip et al., BMC Infectious Disea... Hydroxychloroquine in the treatment of outpatients with mildly symptom... 55% lower mortality (p=0.43) and 37% lower hospitalization (p=0.04). Retrospective 1,274 outpatients, 47% re...



Di Castelnuovo et al., Europe... Use of hydroxychloroquine in hospitalised COVID-19 patients is associat... 30% lower mortality (p<0.0001). Retrospective 3,451 hospitalized patients, 30% reduction in mortality with HC...



Connor et al., NCT04352946 HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial (HE... Estimated 374 participant HCQ prophylaxis RCT with results not reported over 3 years after estimated complet...



Catteau et al., Int. J. Antimicr... Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Pati... 32% lower mortality (p<0.0001). Retrospective 8,075 hospitalized patients, 4,542 low-dose HCQ, 3,533 control...



Pasquini et al., Journal of Anti... Effectiveness of remdesivir in patients with COVID-19 under mechanical ... 16% lower mortality (p=0.34). Retrospective 51 ICU patients under mechanical ventilation, 33 treated with HC...



Ly et al., International Journal ... Pattern of SARS-CoV-2 infection among dependant elderly residents livin... 56% lower mortality (p=0.02). Retrospective analysis of retirement homes, HCQ+AZ >= 3 days mortality OR 0.3...



Lane et al., The Lancet Rheu... Risk of hydroxychloroquine alone and in combination with azithromycin i... Retrospective study of RA patients using HCQ vs. sulfasalazine (another DMARD). HCQ treatment showed no i...



Gonzalez et al., medRxiv, doi:... The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre,... 27% lower mortality (p=0.06). Retrospective study focused on eosinophil recovery with 9,644 hospitalized pati...



Dubernet et al., J. Global Anti... A comprehensive strategy for the early treatment of COVID-19 with azithr... 88% lower ICU admission (p=0.008). Retrospective analysis of 36 hospitalized patients showing HCQ/AZ assoc...



Prodromos, C., New Microbe... Hydroxychloroquine is protective to the heart, not harmful: A systematic ... Review concluding that HCQ/AZ does not cause Torsade de Pointes or related deaths, HCQ decreases cardiac ...



Pinato et al., Cancer Discover... Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 59% lower mortality (p=0.0001). Restrospective 890 cancer patients with COVID-19, adjusted mortality HR for ...



El-Sherbiny et al., NCT04477... Development and Validation of "Ready-to-Use" Inhalable Forms of Hydro... Estimated 40 patient HCQ inhaled late treatment RCT with results not reported over 3 years after estimated co...



Peters et al., Clinical Microbio... Outcomes of Persons With COVID-19 in Hospitals With and Without Stan... 9% higher mortality (p=0.57). Retrospective study of HCQ use in 9 hospitals in the Netherlands, showing no sig...



Abd-Elsalam et al., American ... Hydroxychloroguine in the Treatment of COVID-19: A Multicenter Rando... This study was retracted.



Roomi et al., J. Medical Intern... Efficacy of hydroxychloroguine and tocilizumab in patients with COVID-1... 38% higher mortality (p=0.54). Retrospective 176 hospitalized patients (144 HCQ, 32 control) showing no signi...



Pablos et al., Annals of the Rh... Clinical outcomes of hospitalised patients with COVID-19 and chronic in... 126% higher severe cases (p=0.002). Retrospective 228 rheumatic disease and 228 non-rheumatic disease ho...



Tarek et al., European Journal... Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-1... In Silico analysis of HCQ treatment showing concluding that HCQ may affect viral clearance if administered ear...



The effect of 5-day course of hydroxychloroguine and azithromycin com... Bakhshaliyev et al., J. Electro... Safety study of 109 patients showing 5 days of HCQ+AZ did not lead to clinically significant QT prolongation or...



Saleemi et al., medRxiv, doi:1... Time to negative PCR from symptom onset in COVID-19 patients on Hydr... 21% slower viral clearance (p=0.05). Retrospective 65 HCQ+AZ, 20 control patients, showing median time to n...



Lopez et al., Int. J. Antimicrob... Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patient... Small retrospective study of 29 ICU patients comparing those with HCQ plasma concentration within target to ...



Salvarani et al., Arthritis & Rh... Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Popu... 6% fewer cases (p=0.75). Comparison of CQ/HCQ users with the general population in a region of Italy, showin...



McCullough et al., The Ameri... Pathophysiological Basis and Rationale for Early Outpatient Treatment of... Review of pathophysiological principles related to early outpatient treatment and therapeutic approaches inclu...



Watanabe et al., Open Letter Concerns regarding the misinterpretation of statistical hypothesis testin... Open letter signed by 38 professors and doctors regarding misinterpretation of statistics in HCQ RCTs. Author...



Singer et al., Annals of the Rh... Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rh... 9% more cases (p=0.62). Comparison of the percentage of SLE/RA patients on immunosuppressants that were...



Kalligeros et al., Journal of Gl... Hydroxychloroguine use in hospitalised patients with COVID-19: An obse... 67% higher mortality (p=0.57). Small retrospective database analysis of 36 patients receiving HCQ not showin...



Kamran et al., medRxiv, doi:1... Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A r...

5% lower progression (p=1) and 26% improved viral clearance (p=0.001). Study of 349 low-risk hospitalized pa...



Berenguer et al., Clinical Micr... Characteristics and predictors of death among 4035 consecutively hospi... 18% lower mortality (*p*=0.0001). Retrospective 4035 hospitalized patients in Spain showing reduced mortality ...



Yu et al., Science China Life S... Beneficial effects exerted by hydroxychloroquine in treating COVID-19 pa... 83% lower progression (p=0.05) and 85% lower mortality (p=0.02). Retrospective 2,882 patients in China, medi...



Davido et al., Int. J. Antimicro... Impact of medical care including anti-infective agents use on the progno... 55% lower combined intubation/hospitalization (p=0.04). Retrospective of 132 hospitalized patients. HCQ+AZ(...



Sheaff, R., bioRxiv, doi:10.110... A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine A... In Vitro study presenting a new theory on SARS-CoV-2 infection and why HCQ/CQ provides benefits, which pot...



Bernabeu-Wittel et al., J. Gero... Effectiveness of a On-Site Medicalization Program for Nursing Homes wi... 59% lower mortality (p=0.03). Retrospective 272 nursing home residents showing significantly improved surviv...



A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 In... Estimated 660 participant HCQ prophylaxis RCT with results not reported over 3 years after estimated complet...



Mežnar et al., NCT04355026 Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 P... Estimated 90 patient HCQ late treatment RCT with results not reported over 3 years after estimated completion.



Mazzitelli et al., Travel Medici... Apparent inefficacy of hydroxychloroquine combined with azithromycin o... Report on HCQ+AZ use in 41 elderly high-risk patients. 29 of 30 patients with treatment >= 5 days survived. On...



D'Arminio Monforte et al., Int. ... Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and d... 34% lower mortality (p=0.12). HCQ+AZ adjusted death HR 0.44, p=0.009. Propensity scores include baseline C...



BaŞaran et al., Turk. J. Med. S... Outcome of Non-Critical COVID-19 Patients with Early Hospitalization an... Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ, 113 with H...



Novartis, NCT04358081 Hydroxychloroquine Monotherapy and in Combination With Azithromyci... 71% higher hospital discharge (p=0.42), 71% greater improvement (p=0.42), and **79% worse viral clearance** (p...



Santos et al., Clinical Rheuma... Determinants of COVID-19 disease severity in patients with underlying rh... 92% lower mortality (p=0.19). Prospective study of 38 hospitalized rheumatic disease patients with COVID-19 i...



Mitjà et al., NEJM, doi:10.105... A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covi... 46% lower mortality (p=0.39), 17% lower hospitalization (p=0.71), and 32% fewer cases (p=0.27). For positive s...

https://c19hcq.org 35/49



Khurana et al., medRxiv, doi:1... Prevalence and clinical correlates of COVID-19 outbreak among healthca... 51% fewer cases (p=0.02). Study of hospital health care workers showing HCQ prophylaxis reduces COVID-19 ...



Cavalcanti et al., NEJM, doi:1... Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate C... 16% lower mortality (p=0.77) and 28% higher hospitalization (p=0.3). Late stage RCT of 667 hospitalized patie...



Kadnur et al., Journal of Famil... Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among heal... 62% fewer cases (p=0.01). Prophylaxis study with 334 low-risk healthcare workers in India, showing significant...



Ou et al., PLOS Pathogens, do... Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuat... In Vitro analysis showing that HCQ efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, ...



Hoffmann et al., Nature, (202... Chloroquine does not inhibit infection of human lung cells with SARS-Co... The title of this paper does not appear to match the results. Fig. 1b @100uM shows CQ results in a ~4.5 fold ...



Utilization of COVID-19 Treatments and Clinical Outcomes among Patien... Rivera et al., Cancer Discover... 2% higher mortality (p=0.92). Retrospective cancer patients, showing adjusted OR 1.03 [0.62-1.73] for HCQ. T...



Kelly et al., British Journal of ... Clinical outcomes and adverse events in patients hospitalised with COVI... 143% higher mortality (p=0.03). Retrospective 82 hospitalized patients HCQ/AZ, 52 SOC, not finding statisticall...



Bernaola et al., medRxiv, doi:... Observational Study of the Efficiency of Treatments in Patients Hospitaliz... 17% lower mortality (p<0.0001). HCQ HR 0.83 [0.77-0.89] based on propensity score matched retrospective a...



Krishnan et al., J Clin Anesth.,... Clinical comorbidities, characteristics, and outcomes of mechanically ve... 20% lower mortality (p=0.48). Retrospective 152 mechanically ventilated patients in the USA showing unadjust...



Desbois et al., Research Squa... Prevalence and clinical features of COVID-19 in a large cohort of 199 pati... 17% fewer cases (p=1). Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0....



Risch, H., American Journal o... Response to: "Early Outpatient Treatment of Symptomatic, High-Risk Co... Updated meta analysis including 7 new studies of high-risk outpatients, for a total of 12 studies, all showing si...



Watanabe, M., arXiv.org, arXiv... Efficacy of Hydroxychloroquine as Prophylaxis for Covid-19 Secondary analysis of Boulware et al.'s PEP trial and treatment delay-response data, confirming that HCQ is eff...



McGrail et al., medRxiv, doi:1... COVID-19 Case Series at UnityPoint Health St. Luke's Hospital in Cedar R... 70% higher mortality (p=0.69). HCQ+AZ early in the epidemic had a fairly good success rate with few complica...

Lyngbakken et al., Nature Co... A pragmatic randomized controlled trial reports lack of efficacy of hydrox...

4% lower mortality (p=1) and 71% improved viral reduction rate (p=0.51). Small RCT of nasopharyngeal viral lo...



Hong et al., Infect. Chemother... Early Hydroxychloroquine Administration for Rapid Severe Acute Respirat... 65% improved viral clearance (p=0.001). HCQ 1-4 days from diagnosis was the only protective factor against p...



Skipper et al., Annals of Intern... Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A R... 37% lower combined mortality/hospitalization (*p*=0.58), 49% lower hospitalization (*p*=0.38), and 20% improve...



Mitjà et al., Clinical Infectious ... Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A R... 16% lower hospitalization (*p*=0.64), 34% improved recovery (*p*=0.38), and 2% improved viral clearance. This p...



Gupta et al., JAMA Intern. Me... Factors Associated With Death in Critically III Patients With Coronavirus ... 6% higher mortality (p=0.41). Analysis of 2215 intensive care unit patients showing no significant differences w...



Kavanagh et al., Med. Hypoth... Inhaled hydroxychloroquine to improve efficacy and reduce harm in the t... Proposal to use an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatme...



Trullàs et al., Research Squar... High in-hospital mortality due to COVID-19 in a community hospital in Sp... 36% lower mortality (*p*=0.12). Retrospective 100 hospitalized patients in Spain showing lower mortality with H...



Chowdhury et al., Eurasian Jo... A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-A... Small 116 patient RCT comparing ivermectin+doxycycline and HCQ+AZ, not showing a significant difference in...



Lecronier et al., Critical Care, ... Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of c... 42% lower mortality (p=0.24), 6% lower treatment escalation (p=0.73), and 15% improved viral clearance (p=0...



Cravedi et al., American Jour... COVID-19 and kidney transplantation: Results from the TANGO Internatio... 53% higher mortality (p=0.17). Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality ...



Chen et al., PLoS ONE, doi:10... A Multicenter, randomized, open-label, controlled trial to evaluate the effi... 24% improved viral clearance (p=0.71). 2 very small studies with hospitalized patients in Taiwan. RCT with 21 t...



Rivera-Izquierdo et al., Medici... Agentes terapéuticos utilizados en 238 pacientes hospitalizados por CO... 19% lower mortality (p=0.75). Retrospective 238 hospitalized patients in Spain showing lower mortality with H...



Raoult et al., Preprint Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Resu...

Updated meta analysis showing significant reductions in mortality and viral shedding. Mortality OR 0.53 [0.4-0....



Smith et al., NCT04358068 Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Preve... 64% lower hospitalization (p=1) and 10% slower recovery. Early terminated NIAID RCT for HCQ. Patients >60 ...

https://c19hcq.org 37/49



Marzolini et al., Antimicrobial ... Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir a... Study of Lopinivar and HCQ plasma concentrations and CRP levels in late stage (treatment initiation median 8 ...



Li et al., Cell Death & Disease ... Is hydroxychloroquine beneficial for COVID-19 patients?

Review of the anti-inflammatory, antiviral, and protective vascular effects of CQ and HCQ, noting that HCQ may...



Goldstein, L., Preprint, July 7, ... Hydroxychloroquine-based COVID-19 Treatment, A Systematic Review of... 85% of globally surveyed physicians recognized HCQ as at least partially effective in treating COVID-19, accor...



An et al., medRxiv, doi:10.110... Treatment Response to Hydroxychloroquine and Antibiotics for mild to m... 3% faster viral clearance (p=0.92). Retrospective of hospitalized patients with 31 HCQ patients and 195 standa...



Niriella et al., Trials, doi:10.11... Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among ... 402 participant HCQ prophylaxis RCT with results not reported over 3 years after completion. Authors note 28...



Derwand et al., International J... COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Lo... 79% lower mortality (p=0.12) and 82% lower hospitalization (p=0.001). 79% lower mortality and 82% lower hos...



Zhong et al., Lancent Rheuma... COVID-19 in patients with rheumatic disease in Hubei province, China: a ... 91% fewer cases (p=0.04). Rheumatic disease patients on HCQ had a lower risk of COVID-19 than those on ot...



Arshad et al., Int. J. Infect. Dis... Treatment with Hydroxychloroquine, Azithromycin, and Combination in P... 51% lower mortality (p=0.009). HCQ decreases mortality from 26.4% to 13.5% (HCQ) or 20.1% (HCQ+AZ). Pro...



Samuel et al., Heart Rhythm, ... Incidence of arrhythmias and electrocardiographic abnormalities in sym... In pediatric patients with PCR positive active COVID-19 infection, significant arrhythmias are infrequent, but oc...



Martinez-Lopez et al., Blood ... Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics an... 33% lower mortality (p=0.2). Retrospective 167 multiple myeloma patients in Spain, showing no significant diff...



Mikami et al., J. Gen. Intern. ... Risk Factors for Mortality in Patients with COVID-19 in New York City 47% lower mortality (p<0.0001). HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not ...



Komissarov et al., medRxiv, d... Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx o... 25% worse viral load (p=0.45). Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 c...



Sosa-García et al., Cir Cir. 20... Experience in the management of severe COVID-19 patients in an intensi... 11% higher mortality (p=1). Small retrospective study of 56 ICU patients in Mexico showing HCQ RR 1.1, p=1.0.

Ferreira et al., J. Medical Virol... Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection

47% fewer cases (p<0.0001). Chronic treatment with HCQ provides protection against COVID, odds ratio 0.51 (...



Mfeukeu-Kuate et al. Electrocardiographic safety of daily Hydroxychloroquine 400mg plus Azit...

No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients treated am...



Farooq et al., NCT04328272 Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid)
Estimated 75 patient HCQ late treatment RCT with results not reported over 3 years after estimated completion.



Gendebien et al., Annals of th... Systematic analysis of COVID-19 infection and symptoms in a systemic l... 4% fewer cases (p=0.93). Small study of SLE patients taking HCQ with a phone survey for COVID-19 suggestive...



Lagier et al., Travel Med. Infec... Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/... 59% lower mortality (p=0.05). Early treatment leads to significantly better clinical outcome and faster viral load...



Bousquet et al., Aging, 12:12,... ADL-dependency, D-Dimers, LDH and absence of anticoagulation are ind... 43% lower mortality (p=0.15). Observational prospective 108 hospitalized patients 65 and older, showing HCQ ...



Butler et al., PRINCIPLE PRINCIPLE: A clinical trial evaluating treatments for suspected and confir...

Estimated 400 patient HCQ early treatment RCT with results not reported over 3 years after estimated complet...



Isaksen et al., medRxiv, doi:1... Chloroquine, but not hydroxychlorquine, prolongs the QT interval in a pri... Safety analysis in patients without COVID-19, finding a small increase in QTc associated with use of CQ, but no...



Fontana et al., Clinical Kidney ... SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centr... 50% lower mortality (p=0.53). Very small observational study of 15 dialysis patients showing HCQ mortality RR ...



Chen et al., medRxiv, doi:10.1... Efficacy and safety of chloroquine or hydroxychloroquine in moderate typ... 20% faster recovery (p=0.51) and 71% faster viral clearance (p=0.0004). RCT 48 hospitalized patients in China ...



Faíco-Filho et al., Braz J Micr... No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in ... 81% improved viral reduction rate (p=0.4). Viral load comparison for 34 HCQ and 32 control patients hospitaliz...



SMSH Sawai Man Singh Hos... HCQ beneficial as preventive drug: SMS doctors told ICMR

PrEP with 4,300 very high risk healthcare workers in a hospital with up to 500+ COVID patients at a time, only ...



NIH, study not available yet NIH halts clinical trial of hydroxychloroquine NIH halts late stage trial reporting no harm and no benefit. 470 patients.



Sbidian et al., medRxiv, doi:1... Hydroxychloroquine with or without azithromycin and in-hospital mortali... 5% higher mortality (p=0.74) and 20% higher hospital discharge (p=0.002). Retrospective of 4,642 hospitalized...



Kaptein et al., bioRxiv, doi:10.... Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infec... Animal study with Syrian hamsters, showing treatment of SARS-CoV-2-infected hamsters with favipiravir or HC...



Treluyer et al., PREP-COVID, N... Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus (P... 122 participant HCQ prophylaxis RCT with results not reported over 3 years after completion.



Paccoud et al., Clinical Infecti... Compassionate use of hydroxychloroquine in clinical practice for patient... 11% lower mortality (p=0.88). Retrospective of 89 hospitalized patients, survival HR 0.89 [0.23-3.47], not statis...



Capucci et al., J. Cardiovasc. ... Low hospitalization rate without severe arrhythmias: a prospective surve... Prospective analysis of early treatment of 350 patients in Italy (without waiting for PCR results), showing low h...



Xue et al., J. Med. Virology, J... Hydroxychloroquine treatment in COVID-19: a descriptive observational ... 30 hospitalized patients. Early use of HCQ is more effective, 43% reduction in progression from moderate to s...



Luo et al., Annals of Oncology... COVID-19 in patients with lung cancer 2% higher mortality (p=0.99). Analysis of hospitalized lung cancer patients with 35 of 48 taking HCQ, mortality ...



Kim et al., Korean J Intern Me... Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clini... Small retrospective study of hospitalized patients with 31 lopinavir-ritonavir and 34 HCQ patients, HCQ 400mq...



Huang et al., Annals of the Rh... Clinical characteristics of 17 patients with COVID-19 and systemic autoi... 80% lower hospitalization (p=0.001). Analysis of 1255 COVID-19 patients in Wuhan Tongji Hospital finding 0.6...



Scherrmann, AAPS J 22, 86 (... Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic E... Proposes a new mechanism supporting the synergistic interaction between HCQ+AZ.



Giacomelli et al., Journal of M... Early administration of lopinavir/ritonavir plus hydroxychloroquine does n... Late stage study of hospitalized patients comparing treatment starting within 5 days versus later. Note that "ea...



Wang et al., medRxiv, doi:10.... Comorbidity and Sociodemographic determinants in COVID-19 Mortality... 6% lower mortality (p=0.63). Database analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odd...



Otea et al., medRxiv, doi:10.1... A short therapeutic regimen based on hydroxychloroquine plus azithrom... 80 moderate cases, HCQ+AZ appears to reduce serious complications and death. Moderate treated cases res...



Pirnay et al., Hosp. Pharm. an... Beneficial effect of Hydroxychloroguine-Azithromycin combination in the ... 68 very high risk nursing home residents, median age 86, HCQ+AZ early treatment within 2.5 days onset, 2 sto...



Bhattacharya et al., medRxix, ... Pre exposure Hydroxychloroquine use is associated with reduced COVID...

81% fewer cases (p=0.001). HCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.



Roussel et al., New Microbes ... Influence of conflicts of interest on public positions in the COVID-19 era, ... Shows a correlation (Spearman test, p = 0.017) between the amount received from Gilead Sciences and public...



Million et al., New Microbes a... Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Compa... [H]CQ effective and reduces mortality by a factor 3. Meta analysis of 20 studies.



RECOVERY Collaborative Gro... Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Pre... 9% higher mortality (p=0.15) and 15% higher ventilation (p=0.19). RECOVERY trial finds no significant benefit fo...



Boulware et al., NEJM, June ... A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis f... 17% fewer cases (p=0.35). Remote post-exposure prophylaxis RCT reporting "[HCQ] did not prevent illness co...



Al-Kofahi et al., Clin. Pharmac... Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The ... Analysis of HCQ dosing regimens, recommending: PrEP: 800mg loading dose followed by 400mg 2 or 3 times ...



Guérin et al., Asian J. Medicin... Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatient... 65% faster recovery (*p*=0.0001). Mean clinical recovery time reduced from 26 days (SOC) to 9 days, *p*<0.0001 (...



Rogado et al., Lung Cancer, d... Covid-19 and lung cancer: A greater fatality rate?

92% lower mortality (p=0.02). Retrospective 17 hospitalized lung cancer patients showing lower mortality with ...



Chamieh et al., medRxiv 2020... Viral Dynamics Matter in COVID-19 Pneumonia: the success of early trea... HCQ+AZ potentially explains 94.7% success in treating a fairly complex cohort.



Chatterjee et al., Indian J. Me... Healthcare workers & SARS-CoV-2 infection in India: A case-control inve... 67% fewer cases (p=0.001). 4+ doses of HCQ associated with a significant decline in the odds of getting infect...



Huang et al., National Scienc... Preliminary evidence from a multicenter prospective observational study ... 67% faster viral clearance (p=0.0001). 197 CQ patients, 176 control. Mean time to undetectable viral RNA and ...



Goldman et al., NEJM, doi:10.... Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
22% lower mortality (p=0.46). Study focused on remdesivir but with results for HCQ in the supplementary appe...



Kuderer et al., Lancet, June 2... Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort s... 134% higher mortality (p<0.0001). Retrospective 928 cancer patients, showing HCQ OR 1.06 [0.51-2.20]. HCQ...



Gianfrancesco et al., Annals o... Characteristics associated with hospitalisation for COVID-19 in people w... 3% lower hospitalization (p=0.82). Analysis of rheumatic disease patients showing no significant association b...

https://c19hcq.org 41/49



Risch, American Journal of E... Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients... Five studies, including two controlled clinical trials, have demonstrated significant outpatient treatment efficacy.



Ip et al., PLoS ONE, doi:10.13... Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An ... 1% lower mortality (p=0.93). Retrospective study of late stage use on 2,512 hospitalized patients showing no s...



Hraiech et al., Ann. Intensive ... Lack of viral clearance by the combination of hydroxychloroquine and azi... 65% lower mortality (p=0.21) and 3% worse viral clearance (p=1). Retrospective 45 ICU patients, 17 treated wit...



ICMR, Indian Council of Medi... Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis... Healthcare workers on HCQ prophylaxis less likely to get COVID. Significant dose-response relationship. Exten...



Mehra et al., The Lancet, May... Hydroxychloroquine or chloroquine with or without a macrolide for treat... Incorrect at first read (implausible death, ventilation, and population numbers). This paper was retracted.



Luo et al., The American Jour... Metformin Treatment Was Associated with Decreased Mortality in COVI... 32% lower mortality (p=0.72). Retrospective 283 COVID-19+ diabetes patients in China, showing non-statistica...



Singh et al., medRxiv, doi:10.... Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID... 5% lower mortality (p=0.72) and 19% lower ventilation (p=0.26). EHR analysis of 3,372 hospitalized COVID-19 ...



Kim et al., medRxiv, doi:10.11... Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Ant... 51% shorter hospitalization (p=0.01) and 56% faster viral clearance (p=0.005). Retrospective of 97 moderate c...



Ahmad et al., doi:10.1101/20... Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-... 54 patients in long term care facilities. 6% death with HCQ+AZ compared to 22% using a naive indirect compa...



Macias et al., medRxiv, 10.11... Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients wi... 26% lower hospitalization (p=1) and 49% more cases (p=0.53). Very small retrospective study of rheumatic dis...



Yu et al., Science China Life S... Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients... 60% lower mortality (p=0.002). Retrospective, 550 critically ill patients. 19% fatality for HCQ versus 47% for no...



Mahévas et al., BMJ 2020, 36... Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumo... 20% higher mortality (p=0.75). Observational study of 181 patients with advanced disease requiring oxygen sh...



Okour et al., Journal of Pharm... Hydroxychloroquine and azithromycin as potential treatments for COVID... Odds of PCR-positive decrease by 53% for each unit increase in HCQ log-concentration. Similarly, the odds de...

Cassione et al., Annals of the ... COVID-19 infection in a northern-Italian cohort of systemic lupus erythe...

https://c19hcq.org 42/49

50% more cases (p=0.59). Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4...



Shabrawishi et al., medRxix, d... Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to di... 15% improved viral clearance (p=0.66). Retrospective 93 hospitalized patients in Saudi Arabia showing a non-s...



Rosenberg et al., JAMA, May ... Association of Treatment With Hydroxychloroquine or Azithromycin With ... 35% higher mortality (p=0.31). Restrospective observational late stage study showing no significant difference...



Alberici et al., Kidney Int., 98:... A report from the Brescia Renal COVID Task Force on the clinical charact... 43% lower mortality (p=0.12). Analysis of 94 hemodialysis COVID-19 positive patients, showing lower mortality...



Grassin-Delyle et al., Clinical I... Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lu...

On human lung parenchymal explants, CQ concentration clinically achievable in the lung (100µM) inhibited the...



Carlucci et al., J. Med. Microb... Zinc sulfate in combination with a zinc ionophore may improve outcome... Retrospective 932 patients showing that the addition of zinc to HCQ+AZ reduced mortality / transfer to hospic...



Konig et al., Annals of the Rhe... Baseline use of hydroxychloroquine in systemic lupus erythematosus do... 3% lower hospitalization (p=0.88). Analysis of 80 SLE patients diagnosed with COVID-19, showing the frequen...



Derendorf, H., Int. J. Antimicr... Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin Discusses pharmacokinetic properties of HCQ+AZ as a potential underlying mechanism of the observed antivir...



Geleris et al., NEJM, May 7, 2... Observational Study of Hydroxychloroquine in Hospitalized Patients with ... 4% higher combined mortality/intubation (p=0.76). Before propensity matching, 38 control patients had hypert...



Sermo reports: COVID-19 treatment trends over 6 weeks and 33,700 inte...

HCQ used by 55% of physicians worldwide for COVID. Survey of 6,150 physicians.



Maisonnasse et al., Nature, 2... Hydroxychloroquine use against SARS-CoV-2 infection in non-human pri... Monkey study which reports no effect of HCQ or HCQ+AZ. However, there are several signs of effectiveness de...



Membrillo de Novales et al., P... Early Hydroxychloroquine ls Associated with an Increase of Survival in C... 55% lower mortality (p=0.002). 166 patients hospitalised with COVID-19, HCQ increased survival 1.4 - 1.8 time...



Million et al., Travel Med Infec... Early Treatment of COVID-19 Patients With Hydroxychloroquine and Azit... Retrospective 1061 patients. HCQ+AZ safe and results in a low fatality rate.



Gendelman et al., Autoimmun... Continuous Hydroxychloroquine or Colchicine Therapy Does Not Prevent... 8% fewer cases (p=0.88). Very small study of rheumatic disease/autoimmune disorder patients showing no sig...

https://c19hcq.org 43/49



Mitchell et al., SSRN, doi:10.2... Markedly Lower Rates of Coronavirus Infection and Fatality in Malaria-En... 99% lower mortality (p=0.0001). Analysis of COVID-19 amongst 2.4B people shows a wide counterintuitive dis...



Mallat et al., Medicine (Baltim... Hydroxychloroquine is associated with slower viral clearance in clinical C... 203% slower viral clearance (p=0.02). Very small retrospective analysis of 34 patients finding slower binary PC...



Mercuro et al., JAMA Cardiol.,... Risk of QT Interval Prolongation Associated With Use of Hydroxychloroqu... Study of 90 hospitalized patients given HCQ, 53 also receiving AZ, 53% hypertension, 29% diabetes mellitus, b...



Bessière et al., JAMA Cardiol.... Assessment of QT Intervals in a Case Series of Patients With Coronavirus... Study of 40 very serious condition ICU patients, 75% required invasive mechanical ventilation, 63% received va...



Seydi Coronavirus: a study in Senegal confirms the effectiveness of hydroxychl...

Preliminary results of Senegal trial with 181 patients showing faster recovery with HCQ, and even faster recover...



Kim et al., NCT04307693 Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients Wit...
65 patient HCQ early treatment RCT with results not reported over 3 years after completion. This trial was term...



Meo et al., Eur. Rev. Med. Pha... Efficacy of chloroquine and hydroxychloroquine in the treatment of COVI... Analysis of COVID-19 and malaria, finding that COVID-19 is highly pandemic in countries where malaria is least...



Sánchez-Álvarez et al., Nefrol... Status of SARS-CoV-2 infection in patients on renal replacement therapy.... 46% lower mortality (p=0.005). Analysis of 868 patients on renal replacement therapy. Statistically significant r...



Saleh et al., Circulation: Arrhy... The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the ... 201 hospitalized patients. No serious side effects of HCQ. No instances of Torsade de pointes, or arrhythmoge...



Klimke et al., Med. Hypothese... Hydroxychloroquine as an aerosol might markedly reduce and even prev... Proposal to use HCQ as an aerosol in order to reach sufficient therapeutic levels at the alveolar epithelial cells. ...



Auld et al., Critical Care Medi... ICU and ventilator mortality among critically ill adults with COVID-19

3% higher mortality (p=1). Retrospective 217 critically ill patients, 114 receiving HCQ, showing no significant di...



Andreani et al., Microbial Path... In vitro testing of combined hydroxychloroquine and azithromycin on SA... In Vitro study showing that HCQ and AZ have a synergistic effect on SARS-CoV-2 at concentrations compatible...



Ashraf et al., medRxiv doi:10.... COVID-19 in Iran, a comprehensive investigation from exposure to treat... 68% lower mortality (p=0.15). Small limited trial with 100 patients concluding that HCQ improved clinical outco...

40r27

Izoulet M., SSRN, doi:10.2139... Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatmen...

85% lower mortality (p=0.001). Compares the dynamics of daily deaths in the 10 days following the 3rd death i...



Magagnoli et al., Med (2020),... Outcomes of hydroxychloroquine usage in United States veterans hospit... 11% lower mortality (p=0.74). Retrospective 807 hospitalized patients, no statistically significant reduction in ...



Lee at al., Int. J. Antimicrob. A... Can Post-Exposure Prophylaxis for COVID-19 Be Considered as an Outbr... Post exposure prophylaxis of 211 high-risk people after major exposure event in a long term care hospital, sho...



Borba et al., JAMA Network O... Chloroquine diphosphate in two different dosages as adjunctive therapy ... Comparison of typical CQ dosage with high dosage CQ (600mg CQ twice daily for 10 days), showing higher m...



Esper et al., Prevent Senior In... Empirical treatment with hydroxychloroquine and azithromycin for suspe... 64% lower hospitalization (p=0.02). 636 patients. HCQ+AZ reduced hospitalization 79% when used within 7 da...



Brufsky, A., J. Medical Virolog... Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic

Theory on the effectiveness of HCQ. HCQ has been shown to block the polarization of macrophages to an M1 i...



Tang et al., BMJ 2020, 369, d... Hydroxychloroquine in patients with mainly mild to moderate coronaviru... 21% improved viral clearance (p=0.51). 150 patients very late stage RCT showing no significant difference. Tre...



Gao et al., Biosci Trends, May ... Update on Use of Chloroquine/Hydroxychloroquine to Treat Coronavirus ... Increasing evidence from completed clinical studies shows CQ and HCQ effective (HCQ more effective).



Barbosa et al., Preprint Clinical outcomes of hydroxychloroquine in hospitalized patients with CO... 147% higher mortality (p=0.58). Small retrospective study with 63 patients (32 treated with HCQ), showing no ...



Gautret et al., Travel Medicine... Clinical and microbiological effect of a combination of hydroxychloroqui...

Pilot study suggesting improvement with HCQ+AZ and recommending further study. 80 patients with relatively ...



Lover, medRxiv, doi:10.1101/... Quantifying treatment effects of hydroxychloroquine and azithromycin fo... Secondary analysis of Gautret et al. showing "modest to no impact of HCQ treatment, with more significant eff...



Derwand et al., Medical Hypo... Does zinc supplementation enhance the clinical efficacy of chloroquine/... Hypothesis that HCQ/CQ + zinc will be more effective than HCQ/CQ alone for COVID-19.



Fantini et al., Int J Antimicrob ... Structural and molecular modelling studies reveal a new mechanism of a... In Silico analysis confirming the antiviral properties of CQ, showing a new mechanism of action of CQ, and sho...



Huang et al., Journal of Mole... Treating COVID-19 with Chloroquine 92% improved recovery (p=0.02) and 83% lower pneumonia (p=0.22). 22 patients. All CQ patients discharged b...

https://c19hcq.org 45/49



Chen et al., medRxiv doi:10.1... Efficacy of hydroxychloroquine in patients with COVID-19: results of a ra... 57% lower pneumonia (p=0.04). 62 patients. RCT showing significantly faster recovery with HCQ. 13% progres...



Clementi et al., Front. Microbi... Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroq... In Vitro study showing greater inhibition for combined pre and post-exposure treatment for Vero E6 and Caco-...



Molina et al., Médecine et Ma... No evidence of rapid antiviral clearance or clinical benefit with the combi... Report on 11 patients treated with HCQ with no control group. Authors suggest there is no evidence of benefit ...



Zhong Nanshan (钟南山) Efficacy and safety of chloroquine for treatment of COVID-19. An open-la... 80% improved viral clearance (p=0.0001). 197 patients. CQ effective. Day 10 viral RNA negative 91.4% HCQ ver...



Pagliano et al., Clin. Infect. Di... Is Hydroxychloroquine a Possible Post-Exposure Prophylaxis Drug to Lim... CQ and HCQ inhibit replication at early stages of infection, no similar effect reported for other drugs which are ...



Hu et al., Nature Nanotechnol... Insights from nanomedicine into chloroquine efficacy against COVID-19 CQ is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have pote...



ICMR, Indian Council of Medi... Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV... Recommends HCQ for prophylaxis in asymptomatic healthcare workers as found effective in-vitro and in-vivo.



Hu et al., Shanghai Combined... Shanghai Experience of COVID-19 Management Clinical studies of HCQ with 184 cases and 21 hospitals show HCQ is effective.



Liu et al., Cell Discovery 6, 16 ... Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in i... In Vitro study showing that HCQ is effective in vitro and less toxic than CQ. In addition to direct antiviral activity...



Gautret et al., Int. J. of Antimi... Hydroxychloroquine and azithromycin as a treatment of COVID-19: result... 66% improved viral clearance (p=0.001). HCQ was significantly associated with reduction / elimination of viral l...



Sahraei et al., Int. J. Antimicro... Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroq... Discussion of mechanisms of action, CQ vs. HCQ, early studies, safety.



Todaro and Rigano An Effective Treatment for Coronavirus (COVID-19)

Discussion of existing research, treatment guidelines, and mechanisms of action for CQ and HCQ, recommend...



Devaux et al., International Jo... New insights on the antiviral effects of chloroquine against coronavirus: ... Discusses mechanisms of CQ interference with the SARS-CoV-2 replication cycle.

Cortegiani et al., J. Crit. Care,... A Systematic Review on the Efficacy and Safety of Chloroquine for the Tr...

https://c19hcq.org 46/49

Review of six articles and 23 ongoing clinical trials in China recommending research and clinical use adhering ...



Yao et al., Clin. Infect. Dis., 20... In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hy... In Vitro study showing that HCQ is more potent than CQ in vitro for inhibiting SARS-CoV-2. Simulates HCQ con...



Chen et al., J. Zhejiang Univer... A pilot study of hydroxychloroquine in treatment of patients with commo... 29% lower progression (*p*=0.57) and 100% worse viral clearance (*p*=1). 30 moderate hospitalized cases, all rec...



Colson et al., Int J. Antimicro... Chloroquine and Hydroxychloroquine as Available Weapons to Fight COV... Recommending CQ and HCQ for COVID-19 based on 20 clinical studies in China and a strong rationale for use.



Jiang et al., Chin. J. Tuberc. R... Expert Consensus on Chloroquine Phosphate for the Treatment of Novel ... Early trials in China show CQ results in shorter hospital stays and improved patient outcomes.



Gao et al., BioScience Trends,... Breakthrough: Chloroquine phosphate has shown apparent efficacy in tr... Results from 15 clinical trials in China showing CQ is effective.



Sun, Y., deputy head of the Ch... Antimalarial drug confirmed effective on COVID-19 HCQ under clinical trials in >10 hospitals in China and has shown fairly good efficacy.



Xia et al., ChiCTR2000029741 Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel cor... 38% improved viral clearance (p=0.17). Early results from a very small trial, reported within the application for ...



Wang et al., Cell Res. 30, 269... Remdesivir and chloroquine effectively inhibit the recently emerged novel... In Vitro study showing that Remdesivir and CQ potently blocked SARS-CoV-2 infection.



Chhonker et al., Journal of Ch... Simultaneous quantitation of hydroxychloroquine and its metabolites in ...

Presents a method for quantification of HCQ in mouse blood and tissues. They show a lung concentration sign...



Al-Bari, M., Pharmacology Re... Targeting endosomal acidification by chloroquine analogs as a promisin... Review of the use of chloroquine analogs for endosomal low pH dependent viruses including Ebola, Marburg, ...



Browning, D., Pharmacology ... Pharmacology of Chloroquine and Hydroxychloroquine

Review of the pharmacology of CQ and HCQ. Some notable points: - HCQ and CQ are equipotent but CQ is mo...



de Wilde et al., Antimicrobial ... Screening of an FDA-Approved Compound Library Identifies Four Small-... CQ inhibits SARS-CoV, MERS-CoV, and HCoV-229E-GFP replication in the low-micromolar range.



Yan et al., Cell Research, 23, ... Anti-malaria drug chloroquine is highly effective in treating avian influenz... CQ, a known autophagy inhibitor that is in clinical use, can efficiently ameliorate acute lung injury and dramati...



Quinine and antipyrine, a bitherapy for defying death during the Russian influenza pandemic of 1889-1890 (aro...

Edwin Wiley Grove Laxative Bromo Quinine

Quinine was considered effective for respiratory infections as early as 1889.

For search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), PRISMA answers, and statistical methods see methods. Studies with preprints and journal versions are listed under the earlier preprint date.

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not

https://c19hcq.org 48/49

provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Feedba	ack				
Subm	nit				
f Share	Tweet	@CovidAnalysis	FAQ	Public domain CC0 1.0 © 0	